BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617-649. [PMID: 21039302 DOI: 10.3109/07853890.2010.518623] [Cited by in Crossref: 770] [Cited by in F6Publishing: 649] [Article Influence: 70.0] [Reference Citation Analysis]
Number Citing Articles
1 Khan RS, Newsome PN. Non-alcoholic fatty liver disease and liver transplantation. Metabolism. 2016;65:1208-1223. [PMID: 26997540 DOI: 10.1016/j.metabol.2016.02.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
2 Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepat Mon. 2016;16:e34897. [PMID: 27110262 DOI: 10.5812/hepatmon.34897] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
3 Moon HS, Dalamaga M, Kim SY, Polyzos SA, Hamnvik OP, Magkos F, Paruthi J, Mantzoros CS. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev. 2013;34:377-412. [PMID: 23475416 DOI: 10.1210/er.2012-1053] [Cited by in Crossref: 149] [Cited by in F6Publishing: 125] [Article Influence: 18.6] [Reference Citation Analysis]
4 Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328-357. [PMID: 28714183 DOI: 10.1002/hep.29367] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1541] [Article Influence: 494.5] [Reference Citation Analysis]
5 Miyauchi S, Miyake T, Miyazaki M, Eguchi T, Niiya T, Yamamoto S, Senba H, Furukawa S, Matsuura B, Hiasa Y. Insulin-like growth factor-1 is inversely associated with liver fibrotic markers in patients with type 2 diabetes mellitus. J Diabetes Investig 2019;10:1083-91. [PMID: 30592792 DOI: 10.1111/jdi.13000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Kim HN, Joo EJ, Cheong HS, Kim Y, Kim HL, Shin H, Chang Y, Ryu S. Gut Microbiota and Risk of Persistent Nonalcoholic Fatty Liver Diseases. J Clin Med 2019;8:E1089. [PMID: 31344854 DOI: 10.3390/jcm8081089] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
7 Mueller NT, Pereira MA, Demerath EW, Dreyfus JG, MacLehose RF, Carr JJ, Terry JG, Jacobs DR Jr. Earlier menarche is associated with fatty liver and abdominal ectopic fat in midlife, independent of young adult BMI: The CARDIA study. Obesity (Silver Spring) 2015;23:468-74. [PMID: 25521620 DOI: 10.1002/oby.20950] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
8 Olaywi M, Bhatia T, Anand S, Singhal S. Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. Hepatobiliary Pancreat Dis Int. 2013;12:584-588. [PMID: 24322742 DOI: 10.1016/S1499-3872(13)60092-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
9 Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:728-36. [PMID: 32043602 DOI: 10.1111/apt.15660] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 32.0] [Reference Citation Analysis]
10 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45. [DOI: 10.1136/jclinpath-2013-201620] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
11 Machado MV, Diehl AM. Pathogenesis of Nonalcoholic Steatohepatitis. Gastroenterology 2016;150:1769-77. [PMID: 26928243 DOI: 10.1053/j.gastro.2016.02.066] [Cited by in Crossref: 169] [Cited by in F6Publishing: 144] [Article Influence: 33.8] [Reference Citation Analysis]
12 Sandboge S, Perälä M, Salonen MK, Blomstedt PA, Osmond C, Kajantie E, Barker DJP, Eriksson JG. Early growth and non-alcoholic fatty liver disease in adulthood—the NAFLD liver fat score and equation applied on the Helsinki Birth Cohort Study. Annals of Medicine 2013;45:430-7. [DOI: 10.3109/07853890.2013.801275] [Cited by in Crossref: 83] [Cited by in F6Publishing: 20] [Article Influence: 10.4] [Reference Citation Analysis]
13 Chan W, Nik Mustapha NR, Mahadeva S. A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis. Hepatol Int 2015;9:594-602. [DOI: 10.1007/s12072-014-9596-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
14 Lai M, Afdhal NH. Liver Fibrosis Determination. Gastroenterol Clin North Am. 2019;48:281-289. [PMID: 31046975 DOI: 10.1016/j.gtc.2019.02.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
15 Nobili V, Alisi A, Cutrera R, Carpino G, De Stefanis C, D'Oria V, De Vito R, Cucchiara S, Gaudio E, Musso G. Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. Thorax 2015;70:769-81. [PMID: 26069285 DOI: 10.1136/thoraxjnl-2015-206782] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
16 Taylor AC, Maddirela D, White SB. Role of Radioembolization for Biliary Tract and Primary Liver Cancer. Surgical Oncology Clinics of North America 2019;28:731-43. [DOI: 10.1016/j.soc.2019.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
17 Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58:1007-1019. [PMID: 23183525 DOI: 10.1016/j.jhep.2012.11.021] [Cited by in Crossref: 237] [Cited by in F6Publishing: 184] [Article Influence: 26.3] [Reference Citation Analysis]
18 Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017;9:679-88. [PMID: 29276410 DOI: 10.2147/CLEP.S144368] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
19 Czul F, Bhamidimarri KR. Noninvasive Markers to Assess Liver Fibrosis. J Clin Gastroenterol 2016;50:445-57. [PMID: 27105176 DOI: 10.1097/MCG.0000000000000534] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
20 Bedogni G, Gastaldelli A, Tiribelli C, Agosti F, De Col A, Fessehatsion R, Sartorio A. Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. J Endocrinol Invest 2014;37:739-44. [PMID: 24906975 DOI: 10.1007/s40618-014-0101-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
21 Holterman A, Gurria J, Tanpure S, Disomma N. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Seminars in Pediatric Surgery 2014;23:49-57. [DOI: 10.1053/j.sempedsurg.2013.10.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
22 Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530. quiz e60. [PMID: 21440669 DOI: 10.1016/j.cgh.2011.03.020] [Cited by in Crossref: 645] [Cited by in F6Publishing: 552] [Article Influence: 64.5] [Reference Citation Analysis]
23 Hwang H, Jung TW, Hong HC, Seo JA, Kim SG, Kim NH, Choi KM, Choi DS, Baik SH, Yoo HJ. LECT2 induces atherosclerotic inflammatory reaction via CD209 receptor-mediated JNK phosphorylation in human endothelial cells. Metabolism 2015;64:1175-82. [DOI: 10.1016/j.metabol.2015.06.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
24 Mishra A, Younossi ZM. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:135-144. [PMID: 25755422 DOI: 10.1016/s0973-6883(12)60102-9] [Cited by in Crossref: 51] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
25 Cheung A, Figueredo C, Rinella ME. Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. Am J Gastroenterol 2019;114:579-90. [PMID: 30839326 DOI: 10.14309/ajg.0000000000000058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
26 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ;  American Gastroenterological Association;  American Association for the Study of Liver Diseases;  American College of Gastroenterologyh. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592-1609. [PMID: 22656328 DOI: 10.1053/j.gastro.2012.04.001] [Cited by in Crossref: 1078] [Cited by in F6Publishing: 940] [Article Influence: 119.8] [Reference Citation Analysis]
27 Goulart AC, Oliveira IR, Alencar AP, Santos MS, Santos IS, Martines BM, Meireles DP, Martines JA, Misciagna G, Benseñor IM, Lotufo PA. Diagnostic accuracy of a noninvasive hepatic ultrasound score for non-alcoholic fatty liver disease (NAFLD) in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Sao Paulo Med J 2015;133:115-24. [PMID: 26018881 DOI: 10.1590/1516-3180.2014.9150812] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
28 Liang Y, Liang S, Zhang Y, Deng Y, He Y, Chen Y, Liu C, Lin C, Yang Q. Oral Administration of Compound Probiotics Ameliorates HFD-Induced Gut Microbe Dysbiosis and Chronic Metabolic Inflammation via the G Protein-Coupled Receptor 43 in Non-alcoholic Fatty Liver Disease Rats. Probiotics Antimicrob Proteins. 2019;11:175-185. [PMID: 29353414 DOI: 10.1007/s12602-017-9378-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 19.0] [Reference Citation Analysis]
29 Kumar R, Priyadarshi RN, Anand U. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. J Clin Transl Hepatol 2020;8:76-86. [PMID: 32274348 DOI: 10.14218/JCTH.2019.00051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
30 Chan WK, Nik Mustapha NR, Wong GL, Wong VW, Mahadeva S. Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population. United European Gastroenterol J 2017;5:76-85. [PMID: 28405325 DOI: 10.1177/2050640616646528] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
31 Valva P, Ríos DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol 2016;22:1367-81. [PMID: 26819506 DOI: 10.3748/wjg.v22.i4.1367] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
32 Ghaeni Pasavei A, Mohebbati R, Jalili-Nik M, Mollazadeh H, Ghorbani A, Nosrati Tirkani A, Taraz Jamshidi S, Hashemy SI, Heidarian Miri H, Soukhtanloo M. Effects of Rhus coriaria L. hydroalcoholic extract on the lipid and antioxidant profile in high fat diet-induced hepatic steatosis in rats. Drug Chem Toxicol 2021;44:75-83. [PMID: 33319629 DOI: 10.1080/01480545.2018.1533024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Williams KH, Vieira De Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Brooks B, Bu Y, Cavanagh E, Raleigh J, McLennan SV. Circulating dipeptidyl peptidase-4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non-alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross-sectional study. J Diabetes. 2015;7:809-819. [PMID: 25350950 DOI: 10.1111/1753-0407.12237] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
34 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 2014;20:10851-63. [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 55] [Article Influence: 11.2] [Reference Citation Analysis]
35 Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med. 2015;21:645-662. [PMID: 26432021 DOI: 10.1016/j.molmed.2015.08.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 11.2] [Reference Citation Analysis]
36 Dutra JDM, Lisboa QC, Ferolla SM, Carvalho CMML, Mendes CCM, Ferrari TCA, Couto CA. Vitamin D levels are not associated with non-alcoholic fatty liver disease severity in a Brazilian population. Int J Vitam Nutr Res 2020;:1-8. [PMID: 32639223 DOI: 10.1024/0300-9831/a000667] [Reference Citation Analysis]
37 Doycheva I, Cui J, Nguyen P, Costa EA, Hooker J, Hofflich H, Bettencourt R, Brouha S, Sirlin CB, Loomba R. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2016;43:83-95. [PMID: 26369383 DOI: 10.1111/apt.13405] [Cited by in Crossref: 109] [Cited by in F6Publishing: 82] [Article Influence: 18.2] [Reference Citation Analysis]
38 van Eekelen E, Beulens JWJ, Geelen A, Schrauwen-Hinderling VB, Lamb H, de Roos A, Rosendaal F, de Mutsert R. Consumption of Alcoholic and Sugar-Sweetened Beverages is Associated with Increased Liver Fat Content in Middle-Aged Men and Women. J Nutr 2019;149:649-58. [PMID: 30949667 DOI: 10.1093/jn/nxy313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
39 Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol 2018;18:3. [PMID: 29304731 DOI: 10.1186/s12876-017-0736-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
40 Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl Res. 2012;159:477-486. [PMID: 22633099 DOI: 10.1016/j.trsl.2011.12.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 8.8] [Reference Citation Analysis]
41 Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309. [PMID: 24978903 DOI: 10.1038/ncomms5309] [Cited by in Crossref: 307] [Cited by in F6Publishing: 274] [Article Influence: 43.9] [Reference Citation Analysis]
42 Wong GL. Transient elastography: Kill two birds with one stone? World J Hepatol 2013;5:264-74. [PMID: 23717737 DOI: 10.4254/wjh.v5.i5.264] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 7.4] [Reference Citation Analysis]
43 Farrell GC, van Rooyen D, Gan L, Chitturi S. NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver. 2012;6:149-171. [PMID: 22570745 DOI: 10.5009/gnl.2012.6.2.149] [Cited by in Crossref: 247] [Cited by in F6Publishing: 217] [Article Influence: 27.4] [Reference Citation Analysis]
44 Mehta R, Jeiran K, Koenig AB, Otgonsuren M, Goodman Z, Baranova A, Younossi Z. The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). BMC Med Genet 2016;17:63. [PMID: 27596100 DOI: 10.1186/s12881-016-0324-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
45 Bush H, Golabi P, Younossi ZM. Pediatric Non-Alcoholic Fatty Liver Disease. Children (Basel) 2017;4:E48. [PMID: 28598410 DOI: 10.3390/children4060048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
46 Chen PC, Kao WY, Cheng YL, Wang YJ, Hou MC, Wu JC, Su CW. The correlation between fatty liver disease and chronic kidney disease. J Formos Med Assoc. 2020;119:42-50. [PMID: 30876789 DOI: 10.1016/j.jfma.2019.02.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
47 Wong GL, Chan HL. Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. Hepatol Int 2015;9:481-3. [DOI: 10.1007/s12072-015-9625-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
48 Yu C, Wang L, Xue H, Lin H, Li Y, Chan S. Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes. Clinics and Research in Hepatology and Gastroenterology 2019;43:58-66. [DOI: 10.1016/j.clinre.2018.08.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
49 Gunn NT, Shiffman ML. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom. Clin Liver Dis 2018;22:109-19. [PMID: 29128050 DOI: 10.1016/j.cld.2017.08.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
50 Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology. 2017;65:828-835. [PMID: 28035771 DOI: 10.1002/hep.28917] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 10.8] [Reference Citation Analysis]
51 Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-pollack R, Plodkowski R. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines Formedical Care of Patients with Obesity. Endocrine Practice 2016;22:1-203. [DOI: 10.4158/ep161365.gl] [Cited by in Crossref: 406] [Cited by in F6Publishing: 130] [Article Influence: 81.2] [Reference Citation Analysis]
52 Kwak M, Kim D. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease. Curr Hepatology Rep 2015;14:69-76. [DOI: 10.1007/s11901-015-0258-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
53 Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2016;61:1246-1267. [PMID: 26809873 DOI: 10.1007/s10620-016-4040-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 12.6] [Reference Citation Analysis]
54 Carbone LJ, Angus PW, Yeomans ND. Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:23-31. [PMID: 26111358 DOI: 10.1111/jgh.13026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 10.6] [Reference Citation Analysis]
55 Kumar R, Boon-Bee Goh G. Chronic hepatitis B and fatty liver: Issues in clinical management. Clin Res Hepatol Gastroenterol 2016;40:755-9. [PMID: 26850361 DOI: 10.1016/j.clinre.2015.12.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
56 Zelber-sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-kaluski D, Halpern Z, Santo E, Oren R. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int 2013;33:1406-12. [DOI: 10.1111/liv.12200] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
57 Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L, De Vincentis A, Dell'Unto C, Vorini F, Morini S, Riva E, Picardi A. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol 2016;51:967-73. [PMID: 27150500 DOI: 10.3109/00365521.2016.1161066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
58 Yao Z, Liu XC, Gu YE. Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats. Afr J Tradit Complement Altern Med 2014;11:222-7. [PMID: 24653581 DOI: 10.4314/ajtcam.v11i1.35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
59 Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Dhalwani NN, Kendrick S, Celis-Morales C, Waterworth DM, Alazawi W, Sattar N. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ. 2019;367:l5367. [PMID: 31594780 DOI: 10.1136/bmj.l5367] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 34.0] [Reference Citation Analysis]
60 Williams KH, Viera de Ribeiro AJ, Prakoso E, Veillard AS, Shackel NA, Bu Y, Brooks B, Cavanagh E, Raleigh J, McLennan SV, McCaughan GW, Bachovchin WW, Keane FM, Zekry A, Twigg SM, Gorrell MD. Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity. Diabetes Res Clin Pract 2015;108:466-72. [PMID: 25836944 DOI: 10.1016/j.diabres.2015.02.024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
61 Gitto S, Vitale G, Villa E, Andreone P. Treatment of nonalcoholic steatohepatitis in adults: present and future. Gastroenterol Res Pract. 2015;2015:732870. [PMID: 25866507 DOI: 10.1155/2015/732870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
62 Emamat H, Ghalandari H, Tangestani H, Abdollahi A, Hekmatdoost A. Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism. EXCLI J 2020;19:620-6. [PMID: 32483408 DOI: 10.17179/excli2020-1226] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
63 Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol 2017;5:67-75. [PMID: 28507929 DOI: 10.14218/JCTH.2016.00061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
64 Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61:506-514. [PMID: 25251399 DOI: 10.1002/hep.27490] [Cited by in Crossref: 287] [Cited by in F6Publishing: 249] [Article Influence: 47.8] [Reference Citation Analysis]
65 Wattacheril J, Chalasani N. Nonalcoholic fatty liver disease (NAFLD): is it really a serious condition? Hepatology 2012;56:1580-4. [PMID: 23038652 DOI: 10.1002/hep.26031] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
66 Arulanandan A, Loomba R. Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Curr Hepatol Rep 2015;14:109-18. [PMID: 26500833 DOI: 10.1007/s11901-015-0263-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
67 Siculella L, Tocci R, Rochira A, Testini M, Gnoni A, Damiano F. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5'-UTR in a cellular model of hepatic steatosis. Biochim Biophys Acta 2016;1861:471-81. [PMID: 26869449 DOI: 10.1016/j.bbalip.2016.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
68 Takae M, Fujisue K, Yamamoto E, Egashira K, Komorita T, Oike F, Nishihara T, Yamamoto M, Hirakawa K, Tabata N, Tokitsu T, Yamanaga K, Sueta D, Hanatani S, Nakamura T, Usuku H, Araki S, Arima Y, Takashio S, Suzuki S, Kaikita K, Matsushita K, Tsujita K. Prognostic significance of liver stiffness assessed by fibrosis-4 index in patients with heart failure. ESC Heart Fail 2021. [PMID: 34156170 DOI: 10.1002/ehf2.13351] [Reference Citation Analysis]
69 Simões E Silva AC, Miranda AS, Rocha NP, Teixeira AL. Renin angiotensin system in liver diseases: Friend or foe? World J Gastroenterol 2017;23:3396-406. [PMID: 28596676 DOI: 10.3748/wjg.v23.i19.3396] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 31] [Article Influence: 14.3] [Reference Citation Analysis]
70 De Lucia Rolfe E, Brage S, Sleigh A, Finucane F, Griffin SJ, Wareham NJ, Ong KK, Forouhi NG. Validity of ultrasonography to assess hepatic steatosis compared to magnetic resonance spectroscopy as a criterion method in older adults. PLoS One 2018;13:e0207923. [PMID: 30475885 DOI: 10.1371/journal.pone.0207923] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
71 Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs. 2013;73:1-14. [PMID: 23329465 DOI: 10.1007/s40265-012-0004-0] [Cited by in Crossref: 105] [Cited by in F6Publishing: 89] [Article Influence: 13.1] [Reference Citation Analysis]
72 Yang H, Chang Y, Park S, Jung YS, Park JH, Park DI, Cho YK, Ryu S, Sohn CI. Nonalcoholic Fatty Liver Disease Is Associated with Increased Risk of Reflux Esophagitis. Dig Dis Sci 2017;62:3605-13. [DOI: 10.1007/s10620-017-4805-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol. 2014;6:263-273. [PMID: 24868320 DOI: 10.4254/wjh.v6.i5.263] [Cited by in Crossref: 74] [Cited by in F6Publishing: 53] [Article Influence: 10.6] [Reference Citation Analysis]
74 Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013;52:175-191. [PMID: 23206728 DOI: 10.1016/j.plipres.2012.11.002] [Cited by in Crossref: 215] [Cited by in F6Publishing: 188] [Article Influence: 23.9] [Reference Citation Analysis]
75 Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J 2017;135:277-95. [DOI: 10.1590/1516-3180.2016.0306311216] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
76 Jensen VS, Fledelius C, Zachodnik C, Damgaard J, Nygaard H, Tornqvist KS, Kirk RK, Viuff BM, Wulff EM, Lykkesfeldt J, Hvid H. Insulin treatment improves liver histopathology and decreases expression of inflammatory and fibrogenic genes in a hyperglycemic, dyslipidemic hamster model of NAFLD. J Transl Med 2021;19:80. [PMID: 33596938 DOI: 10.1186/s12967-021-02729-1] [Reference Citation Analysis]
77 Ballestri S, Meschiari E, Baldelli E, Musumeci FE, Romagnoli D, Trenti T, Zennaro RG, Lonardo A, Loria P. Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. Metab Syndr Relat Disord. 2013;11:289-295. [PMID: 23600632 DOI: 10.1089/met.2012.0149] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
78 Tan HL, Zain SM, Mohamed R, Rampal S, Chin KF, Basu RC, Cheah PL, Mahadeva S, Mohamed Z. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J Gastroenterol. 2014;49:1056-1064. [PMID: 23800943 DOI: 10.1007/s00535-013-0850-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
79 Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933-22966. [PMID: 24264040 DOI: 10.3390/ijms141122933] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
80 Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
81 Samejo SA, Abbas Z, Asim M. Effects of anthropometric and metabolic parameters on transaminase levels and liver stiffness in patients with non-alcohol fatty liver disease. Trop Doct 2021;51:185-9. [PMID: 33040692 DOI: 10.1177/0049475520962742] [Reference Citation Analysis]
82 Zelber-sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z, Santo E, Oren R, Shibolet O. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Translational Research 2015;165:428-36. [DOI: 10.1016/j.trsl.2014.10.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 7.3] [Reference Citation Analysis]
83 Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782-9.e4. [PMID: 23860502 DOI: 10.1053/j.gastro.2013.06.057] [Cited by in Crossref: 286] [Cited by in F6Publishing: 238] [Article Influence: 35.8] [Reference Citation Analysis]
84 Han K, Kwon O, Park HJ, Jung SY, Yang C, Son CG. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial. Trials 2020;21:128. [PMID: 32005283 DOI: 10.1186/s13063-020-4068-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
85 Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol 2014;20:9072-89. [PMID: 25083080 DOI: 10.3748/wjg.v20.i27.9072] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
86 Musolino V, Gliozzi M, Bombardelli E, Nucera S, Carresi C, Maiuolo J, Mollace R, Paone S, Bosco F, Scarano F, Scicchitano M, Macrì R, Ruga S, Zito MC, Palma E, Gratteri S, Ragusa M, Volterrani M, Fini M, Mollace V. The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease. J Tradit Complement Med 2020;10:268-74. [PMID: 32670822 DOI: 10.1016/j.jtcme.2020.02.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
87 Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871. [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044] [Cited by in Crossref: 223] [Cited by in F6Publishing: 193] [Article Influence: 27.9] [Reference Citation Analysis]
88 Asrani SK. Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis. Clin Gastroenterol Hepatol 2015;13:2190-204. [PMID: 26226095 DOI: 10.1016/j.cgh.2015.07.030] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
89 Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol. 2017;9:533-543. [PMID: 28469809 DOI: 10.4254/wjh.v9.i11.533] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 19.0] [Reference Citation Analysis]
90 Papachristodoulou A, Kavvadas D, Karamitsos A, Papamitsou T, Chatzidimitriou M, Sioga A. Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer? Pediatr Rep 2021;13:312-21. [PMID: 34201230 DOI: 10.3390/pediatric13020039] [Reference Citation Analysis]
91 Roeb E. Non-alcoholic fatty liver diseases: current challenges and future directions. Ann Transl Med 2021;9:726. [PMID: 33987424 DOI: 10.21037/atm-20-3760] [Reference Citation Analysis]
92 Heianza Y, Arase Y, Tsuji H, Fujihara K, Saito K, Hsieh SD, Tanaka S, Kodama S, Hara S, Sone H. Metabolically healthy obesity, presence or absence of fatty liver, and risk of type 2 diabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 20 (TOPICS 20). J Clin Endocrinol Metab. 2014;99:2952-2960. [PMID: 24823457 DOI: 10.1210/jc.2013-4427] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
93 Goh GB, Kwan C, Lim SY, Venkatanarasimha NK, Abu-Bakar R, Krishnamoorthy TL, Shim HH, Tay KH, Chow WC. Perceptions of non-alcoholic fatty liver disease - an Asian community-based study. Gastroenterol Rep (Oxf). 2016;4:131-135. [PMID: 26463276 DOI: 10.1093/gastro/gov047] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
94 VanWagner LB, Khan SS, Ning H, Siddique J, Lewis CE, Carr JJ, Vos MB, Speliotes E, Terrault NA, Rinella ME, Lloyd-Jones DM, Allen NB. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int 2018;38:706-14. [PMID: 28963767 DOI: 10.1111/liv.13603] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
95 Zhang X, Deng Y, Xiang J, Liu H, Zhang J, Liao J, Chen K, Liu B, Liu J, Pu Y. Galangin Improved Non-Alcoholic Fatty Liver Disease in Mice by Promoting Autophagy. Drug Des Devel Ther 2020;14:3393-405. [PMID: 32884242 DOI: 10.2147/DDDT.S258187] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Ooi GJ, Burton PR, Bayliss J, Raajendiran A, Earnest A, Laurie C, Kemp WW, Mclean CA, Roberts SK, Watt MJ, Brown WA. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study. OBES SURG 2019;29:99-108. [DOI: 10.1007/s11695-018-3479-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
97 Jirapinyo P, Thompson CC. Treatment of NASH with Gastric Bypass. Curr Gastroenterol Rep 2018;20. [DOI: 10.1007/s11894-018-0653-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
98 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 118] [Article Influence: 14.7] [Reference Citation Analysis]
99 Degasperi E, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol. 2016;1:156-164. [PMID: 28404072 DOI: 10.1016/s2468-1253(16)30018-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 24] [Article Influence: 10.8] [Reference Citation Analysis]
100 Belemets N, Kobyliak N, Falalyeyeva T, Kuryk O, Sulaieva O, Vovk T, Beregova T, Ostapchenko L. Polyphenol Compounds Melanin Prevented Hepatic Inflammation in Rats with Experimental Obesity. Natural Product Communications 2018;13:1934578X1801301. [DOI: 10.1177/1934578x1801301118] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
101 Sanna C, Rosso C, Marietti M, Bugianesi E. Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. Int J Mol Sci. 2016;17:pii: E717. [PMID: 27187365 DOI: 10.3390/ijms17050717] [Cited by in Crossref: 93] [Cited by in F6Publishing: 78] [Article Influence: 18.6] [Reference Citation Analysis]
102 Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis. 2012;16:487-504. [PMID: 22824477 DOI: 10.1016/j.cld.2012.05.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
103 Mohammed ED, Abdel-Naim AB, Kangpeng J, Jiang R, Wei J, Sun B. The mother relationship between insulin resistance and non-alcoholic steatohepatitis: Glucosinolates hydrolysis products as a promising insulin resistance-modulator and fatty liver-preventer. Life Sci 2021;264:118615. [PMID: 33096115 DOI: 10.1016/j.lfs.2020.118615] [Reference Citation Analysis]
104 Reyes-garcía R, Rozas-moreno P, Llamoza-torres CJ, Mezquita-raya P. Hígado graso no alcohólico y diabetes. Medicina Clínica 2017;148:33-8. [DOI: 10.1016/j.medcli.2016.08.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Chan W, Treeprasertsuk S, Goh GB, Fan J, Song MJ, Charatcharoenwitthaya P, Duseja A, Dan Y, Imajo K, Nakajima A, Ho K, Goh K, Wong VW. Optimizing Use of Nonalcoholic Fatty Liver Disease Fibrosis Score, Fibrosis-4 Score, and Liver Stiffness Measurement to Identify Patients With Advanced Fibrosis. Clinical Gastroenterology and Hepatology 2019;17:2570-2580.e37. [DOI: 10.1016/j.cgh.2019.03.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 14.5] [Reference Citation Analysis]
106 Ashraf H, Karbalai S, Jamali R. Nonalcoholic fatty liver disease and cardiovascular concerns: The time for hepatologist and cardiologist close collaboration. WJMA 2021;9:164-75. [DOI: 10.13105/wjma.v9.i2.164] [Reference Citation Analysis]
107 Corey KE, Kartoun U, Zheng H, Shaw SY. Development and Validation of an Algorithm to Identify Nonalcoholic Fatty Liver Disease in the Electronic Medical Record. Dig Dis Sci. 2016;61:913-919. [PMID: 26537487 DOI: 10.1007/s10620-015-3952-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
108 Kawanaka M, Nishino K, Nakamura J, Urata N, Oka T, Goto D, Suehiro M, Kawamoto H, Yamada G. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease. Annals of Hepatology 2015;14:837-44. [DOI: 10.5604/16652681.1171767] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
109 Pacana T, Sanyal AJ. Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep. 2015;7:28. [PMID: 25926979 DOI: 10.12703/p7-28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
110 Campbell P, Symonds A, Barritt AS 4th. Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions. Clin Ther 2021;43:500-17. [PMID: 33583577 DOI: 10.1016/j.clinthera.2021.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
111 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol. 2016;7:211-217. [PMID: 27190693 DOI: 10.3349/ymj.2016.57.4.885] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
112 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-S64. [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012] [Cited by in Crossref: 1011] [Cited by in F6Publishing: 838] [Article Influence: 202.2] [Reference Citation Analysis]
113 Perakakis N, Polyzos SA, Yazdani A, Sala-Vila A, Kountouras J, Anastasilakis AD, Mantzoros CS. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study. Metabolism 2019;101:154005. [PMID: 31711876 DOI: 10.1016/j.metabol.2019.154005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 19.5] [Reference Citation Analysis]
114 Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism 2016;65:1136-50. [DOI: 10.1016/j.metabol.2015.09.017] [Cited by in Crossref: 128] [Cited by in F6Publishing: 107] [Article Influence: 25.6] [Reference Citation Analysis]
115 Kawanaka M, Nishino K, Ishii K, Tanikawa T, Urata N, Suehiro M, Sasai T, Haruma K, Kawamoto H. Combination of type IV collagen 7S, albumin concentrations, and platelet count predicts prognosis of non-alcoholic fatty liver disease. World J Hepatol 2021;13:571-83. [PMID: 34131471 DOI: 10.4254/wjh.v13.i5.571] [Reference Citation Analysis]
116 Pan H, Chang H, Lee C. Association between tamoxifen treatment and the development of different stages of nonalcoholic fatty liver disease among breast cancer patients. Journal of the Formosan Medical Association 2016;115:411-7. [DOI: 10.1016/j.jfma.2015.05.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
117 Losekann A, Weston AC, de Mattos AA, Tovo CV, de Carli LA, Espindola MB, Pioner SR, Coral GP. Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients. Int J Mol Sci. 2015;16:25552-25559. [PMID: 26512661 DOI: 10.3390/ijms161025552] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
118 Grabe HJ, Assel H, Bahls T, Dörr M, Endlich K, Endlich N, Erdmann P, Ewert R, Felix SB, Fiene B, Fischer T, Flessa S, Friedrich N, Gadebusch-Bondio M, Salazar MG, Hammer E, Haring R, Havemann C, Hecker M, Hoffmann W, Holtfreter B, Kacprowski T, Klein K, Kocher T, Kock H, Krafczyk J, Kuhn J, Langanke M, Lendeckel U, Lerch MM, Lieb W, Lorbeer R, Mayerle J, Meissner K, zu Schwabedissen HM, Nauck M, Ott K, Rathmann W, Rettig R, Richardt C, Saljé K, Schminke U, Schulz A, Schwab M, Siegmund W, Stracke S, Suhre K, Ueffing M, Ungerer S, Völker U, Völzke H, Wallaschofski H, Werner V, Zygmunt MT, Kroemer HK. Cohort profile: Greifswald approach to individualized medicine (GANI_MED). J Transl Med 2014;12:144. [PMID: 24886498 DOI: 10.1186/1479-5876-12-144] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 5.1] [Reference Citation Analysis]
119 Stål P. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. World J Gastroenterol 2015;21:11077-87. [PMID: 26494963 DOI: 10.3748/wjg.v21.i39.11077] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 57] [Article Influence: 13.8] [Reference Citation Analysis]
120 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23. [DOI: 10.1002/hep.25762] [Cited by in Crossref: 2057] [Cited by in F6Publishing: 1742] [Article Influence: 228.6] [Reference Citation Analysis]
121 Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016;30:282-287. [PMID: 26537011 DOI: 10.1111/jdv.13456] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
122 Davies JMS, Cillard J, Friguet B, Cadenas E, Cadet J, Cayce R, Fishmann A, Liao D, Bulteau AL, Derbré F, Rébillard A, Burstein S, Hirsch E, Kloner RA, Jakowec M, Petzinger G, Sauce D, Sennlaub F, Limon I, Ursini F, Maiorino M, Economides C, Pike CJ, Cohen P, Salvayre AN, Halliday MR, Lundquist AJ, Jakowec NA, Mechta-Grigoriou F, Mericskay M, Mariani J, Li Z, Huang D, Grant E, Forman HJ, Finch CE, Sun PY, Pomatto LCD, Agbulut O, Warburton D, Neri C, Rouis M, Cillard P, Capeau J, Rosenbaum J, Davies KJA. The Oxygen Paradox, the French Paradox, and age-related diseases. Geroscience 2017;39:499-550. [PMID: 29270905 DOI: 10.1007/s11357-017-0002-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
123 Jin R, Le NA, Cleeton R, Sun X, Cruz Muños J, Otvos J, Vos MB. Amount of hepatic fat predicts cardiovascular risk independent of insulin resistance among Hispanic-American adolescents. Lipids Health Dis 2015;14:39. [PMID: 25925168 DOI: 10.1186/s12944-015-0038-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
124 Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes. 2013;4:51-63. [PMID: 23772273 DOI: 10.4239/wjd.v4.i3.51] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 57] [Article Influence: 11.3] [Reference Citation Analysis]
125 Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174-1197. [PMID: 24002776 DOI: 10.1002/hep.26717] [Cited by in Crossref: 301] [Cited by in F6Publishing: 252] [Article Influence: 43.0] [Reference Citation Analysis]
126 Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016;65:1087-1095. [PMID: 26972222 DOI: 10.1016/j.metabol.2016.01.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
127 Keramida G, Potts J, Bush J, Verma S, Dizdarevic S, Peters AM. Accumulation of 18 F-FDG in the Liver in Hepatic Steatosis. American Journal of Roentgenology 2014;203:643-8. [DOI: 10.2214/ajr.13.12147] [Cited by in Crossref: 37] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
128 Pappachan JM, Antonio FA, Edavalath M, Mukherjee A. Non-alcoholic fatty liver disease: a diabetologist’s perspective. Endocrine. 2014;45:344-353. [PMID: 24287794 DOI: 10.1007/s12020-013-0087-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
129 Forlani G, Giorda C, Manti R, Mazzella N, De Cosmo S, Rossi MC, Nicolucci A, Di Bartolo P, Ceriello A, Guida P; AMD-Annals Study Group. The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. J Diabetes Res 2016;2016:2931985. [PMID: 27123461 DOI: 10.1155/2016/2931985] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
130 Lin Y, Gong X, Li X, Shao C, Wu T, Li M, Li F, Ma Q, Ye J, Zhong B. Distinct Cause of Death Profiles of Hospitalized Non-alcoholic Fatty Liver Disease: A 10 Years' Cross-Sectional Multicenter Study in China. Front Med (Lausanne) 2020;7:584396. [PMID: 33511140 DOI: 10.3389/fmed.2020.584396] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Roeters van Lennep J, Averna M, Alonso R. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide. Journal of Clinical Lipidology 2015;9:607-17. [DOI: 10.1016/j.jacl.2015.05.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
132 Zhang B, Ding F, Chen T, Xia LH, Qian J, Lv GY. Ultrasound hepatic/renal ratio and hepatic attenuation rate for quantifying liver fat content. World J Gastroenterol. 2014;20:17985-17992. [PMID: 25548498 DOI: 10.3748/wjg.v20.i47.17985] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
133 Zhang E, Wartelle-Bladou C, Lepanto L, Lachaine J, Cloutier G, Tang A. Cost-utility analysis of nonalcoholic steatohepatitis screening. Eur Radiol. 2015;25:3282-3294. [PMID: 25994191 DOI: 10.1007/s00330-015-3731-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
134 Sturm L, Roth L, Zoldan K, Schultheiss M, Boettler T, Huber JP, Kaeser R, Thimme R, Bettinger D. Blood reelin in the progression of chronic liver disease. Adv Med Sci 2021;66:148-54. [PMID: 33561810 DOI: 10.1016/j.advms.2021.01.006] [Reference Citation Analysis]
135 Liu H, Fu J, Hong R, Liu L, Li F. Acoustic Radiation Force Impulse Elastography for the Non-Invasive Evaluation of Hepatic Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review & Meta-Analysis. PLoS One. 2015;10:e0127782. [PMID: 26131717 DOI: 10.1371/journal.pone.0127782] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 10.7] [Reference Citation Analysis]
136 Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2014;15:7352-7379. [PMID: 24786095 DOI: 10.3390/ijms15057352] [Cited by in Crossref: 79] [Cited by in F6Publishing: 63] [Article Influence: 11.3] [Reference Citation Analysis]
137 Boursier J, Guillaume M, Bouzbib C, Lannes A, Pais R, Smatti S, Cariou B, Bureau C, Ganne-Carrié N, Bourlière M, de Lédinghen V. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF NON-ALCOHOLIC FATTY LIVER DISEASE. Clin Res Hepatol Gastroenterol 2021;:101769. [PMID: 34332133 DOI: 10.1016/j.clinre.2021.101769] [Reference Citation Analysis]
138 Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 2012;36:815-823. [PMID: 22966992 DOI: 10.1111/apt.12046] [Cited by in Crossref: 119] [Cited by in F6Publishing: 117] [Article Influence: 14.9] [Reference Citation Analysis]
139 Xu H, Hsu Y, Chang C, Wei K, Lin C. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatol Int 2016;10:340-6. [DOI: 10.1007/s12072-015-9690-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
140 Sung K, Cha S, Sung J, So M, Byrne CD. Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. Nutrition, Metabolism and Cardiovascular Diseases 2014;24:256-62. [DOI: 10.1016/j.numecd.2013.07.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
141 Athyros VG, Polyzos SA, Kountouras J, Katsiki N, Anagnostis P, Doumas M, Mantzoros CS. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Curr Vasc Pharmacol 2020;18:172-81. [PMID: 30961499 DOI: 10.2174/1570161117666190405164313] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
142 Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138-1153. [PMID: 28314735 DOI: 10.1136/gutjnl-2017-313884] [Cited by in Crossref: 384] [Cited by in F6Publishing: 319] [Article Influence: 96.0] [Reference Citation Analysis]
143 Wah Kheong C, Nik Mustapha NR, Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology 2017;15:1940-1949.e8. [DOI: 10.1016/j.cgh.2017.04.016] [Cited by in Crossref: 70] [Cited by in F6Publishing: 52] [Article Influence: 17.5] [Reference Citation Analysis]
144 Khodadoostan M, Zamanidoost M, Shavakhi A, Sanei H, Shahbazi M, Ahmadian M. Effects of Phlebotomy on Liver Enzymes and Histology of Patients with Nonalcoholic Fatty Liver Disease. Adv Biomed Res 2017;6:12. [PMID: 28299304 DOI: 10.4103/2277-9175.200787] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
145 De A, Duseja A. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. J Clin Exp Hepatol 2020;10:255-62. [PMID: 32405182 DOI: 10.1016/j.jceh.2019.09.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
146 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol. 2014;20:4300-4315. [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 53] [Article Influence: 10.7] [Reference Citation Analysis]
147 VanWagner LB, Ning H, Allen NB, Ajmera V, Lewis CE, Carr JJ, Lloyd-Jones DM, Terrault NA, Siddique J. Alcohol Use and Cardiovascular Disease Risk in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;153:1260-1272.e3. [PMID: 28802566 DOI: 10.1053/j.gastro.2017.08.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
148 Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease 2015;47:181-90. [DOI: 10.1016/j.dld.2014.09.020] [Cited by in Crossref: 371] [Cited by in F6Publishing: 308] [Article Influence: 61.8] [Reference Citation Analysis]
149 Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00177. [PMID: 33102798 DOI: 10.1002/edm2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
150 Verdelho Machado M, Diehl AM. The hedgehog pathway in nonalcoholic fatty liver disease. Crit Rev Biochem Mol Biol 2018;53:264-78. [PMID: 29557675 DOI: 10.1080/10409238.2018.1448752] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
151 Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ. Drug-induced fatty liver disease: An overview of pathogenesis and management. Ann Hepatol 2015;14:789-806. [PMID: 26436351 DOI: 10.5604/16652681.1171749] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
152 Koo BK, Allison MA, Criqui MH, Denenberg JO, Wright CM. The association between liver fat and systemic calcified atherosclerosis. J Vasc Surg 2020;71:204-211.e4. [PMID: 31153702 DOI: 10.1016/j.jvs.2019.03.044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
153 Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, Yang MJ, Lim SG, Kim S, Cheong JY, Cho SW. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis. 2018;50:370-377. [PMID: 29398414 DOI: 10.1016/j.dld.2017.12.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
154 Lahmek P, Meunier N, Michel L, Aubin H, Balester-mouret S. Utilisation de l’élastométrie hépatique comme outil de dépistage de la fibrose hépatique dans un service d’addictologie. La Presse Médicale 2014;43:e17-31. [DOI: 10.1016/j.lpm.2013.07.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
155 Lin SC, Heba E, Wolfson T, Ang B, Gamst A, Han A, Erdman JW, O'Brien WD, Andre MP, Sirlin CB, Loomba R. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique. Clin Gastroenterol Hepatol. 2015;13:1337-1345.e6. [PMID: 25478922 DOI: 10.1016/j.cgh.2014.11.027] [Cited by in Crossref: 123] [Cited by in F6Publishing: 88] [Article Influence: 17.6] [Reference Citation Analysis]
156 Fabbrini E, Magkos F. Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients 2015;7:4995-5019. [PMID: 26102213 DOI: 10.3390/nu7064995] [Cited by in Crossref: 90] [Cited by in F6Publishing: 71] [Article Influence: 15.0] [Reference Citation Analysis]
157 Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology. 2014;147:765-783.e4. [PMID: 25046161 DOI: 10.1053/j.gastro.2014.07.018] [Cited by in Crossref: 365] [Cited by in F6Publishing: 320] [Article Influence: 52.1] [Reference Citation Analysis]
158 Boyle M, Tiniakos D, Schattenberg JM, Ratziu V, Bugianessi E, Petta S, Oliveira CP, Govaere O, Younes R, McPherson S, Bedossa P, Nielsen MJ, Karsdal M, Leeming D, Kendrick S, Anstee QM. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Rep 2019;1:188-98. [PMID: 32039369 DOI: 10.1016/j.jhepr.2019.06.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
159 Chan WK, Ida NH, Cheah PL, Goh KL. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study. J Dig Dis. 2014;15:545-552. [PMID: 25060399 DOI: 10.1111/1751-2980.12175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
160 Elkabbany ZA, Elbarbary NS, Ismail EA, Mohamed NA, Ragab D, Abdel Alem S, Ezzat YM, Maurice SS, Hashem NU. Transient elastography as a noninvasive assessment tool for hepatopathies of different etiology in pediatric type 1 diabetes mellitus. J Diabetes Complications 2017;31:186-94. [PMID: 27742550 DOI: 10.1016/j.jdiacomp.2016.09.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
161 Mlynarsky L, Schlesinger D, Lotan R, Webb M, Halpern Z, Santo E, Shibolet O, Zelber-Sagi S. Non-alcoholic fatty liver disease is not associated with a lower health perception. World J Gastroenterol. 2016;22:4362-4372. [PMID: 27158205 DOI: 10.3748/wjg.v22.i17.4362] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
162 Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014;5:211-8. [PMID: 25018867 DOI: 10.1136/flgastro-2013-100403] [Cited by in Crossref: 135] [Cited by in F6Publishing: 114] [Article Influence: 16.9] [Reference Citation Analysis]
163 Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:1756-67. [PMID: 24587653 DOI: 10.3748/wjg.v20.i7.1756] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
164 Du X, Cai C, Yao J, Zhou Y, Yu H, Shen W. Histone modifications in FASN modulated by sterol regulatory element-binding protein 1c and carbohydrate responsive-element binding protein under insulin stimulation are related to NAFLD. Biochem Biophys Res Commun 2017;483:409-17. [PMID: 28027934 DOI: 10.1016/j.bbrc.2016.12.129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
165 Mitchel EB, Lavine JE. Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1155-1170. [PMID: 25267322 DOI: 10.1111/apt.12972] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
166 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014;20:12956-12980. [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 82] [Article Influence: 17.3] [Reference Citation Analysis]
167 de Carli MA, de Carli LA, Correa MB, Junqueira G, Tovo CV, Coral GP. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease. European Journal of Gastroenterology & Hepatology 2020;32:420-5. [DOI: 10.1097/meg.0000000000001519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
168 AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 2015;16:393-405. [PMID: 25753407 DOI: 10.1111/obr.12271] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
169 Mishra AK, Dubey V, Ghosh AR. Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota. Metabolism. 2016;65:48-65. [PMID: 26683796 DOI: 10.1016/j.metabol.2015.10.008] [Cited by in Crossref: 74] [Cited by in F6Publishing: 57] [Article Influence: 12.3] [Reference Citation Analysis]
170 Takyar V, Nath A, Beri A, Gharib AM, Rotman Y. How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool. Hepatology 2017;66:825-33. [PMID: 28470683 DOI: 10.1002/hep.29247] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
171 Fujii Y, Nouso K, Matsushita H, Kariyama K, Sakurai T, Takahashi Y, Chiba H, Hui S, Ito Y, Ohta M, Okada H. Low-Density Lipoprotein (LDL)-Triglyceride and Its Ratio to LDL-Cholesterol as Diagnostic Biomarkers for Nonalcoholic Steatohepatitis. The Journal of Applied Laboratory Medicine 2020;5:1206-15. [DOI: 10.1093/jalm/jfaa044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
172 Li R, Guo E, Yang J, Li A, Yang Y, Liu S, Liu A, Jiang X. 1,25(OH)2 D3 attenuates hepatic steatosis by inducing autophagy in mice. Obesity (Silver Spring). 2017;25:561-571. [PMID: 28145056 DOI: 10.1002/oby.21757] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
173 Chan WK, Treeprasertsuk S, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Fan JG, Song MJ, Yoon SK, Dan YY, Lesmana L, Ho KY, Goh KL, Wong VW. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Aliment Pharmacol Ther. 2018;47:816-825. [PMID: 29333610 DOI: 10.1111/apt.14506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
174 Golabi P, Sayiner M, Fazel Y, Koenig A, Henry L, Younossi ZM. Current complications and challenges in nonalcoholic steatohepatitis screening and diagnosis. Expert Rev Gastroenterol Hepatol. 2016;10:63-71. [PMID: 26469309 DOI: 10.1586/17474124.2016.1099433] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 5.7] [Reference Citation Analysis]
175 Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, Shin H, Ryu S. Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. Am J Gastroenterol. 2019;114:453-463. [PMID: 30353055 DOI: 10.1038/s41395-018-0283-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
176 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012;107:811-826. [PMID: 22641309 DOI: 10.1038/ajg.2012.128] [Cited by in Crossref: 245] [Cited by in F6Publishing: 216] [Article Influence: 27.2] [Reference Citation Analysis]
177 Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196-205. [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3] [Cited by in Crossref: 150] [Cited by in F6Publishing: 131] [Article Influence: 30.0] [Reference Citation Analysis]
178 Coppell KJ, Miller JC, Gray AR, Schultz M, Mann JI, Parnell WR. Obesity and the extent of liver damage among adult New Zealanders: findings from a national survey. Obes Sci Pract 2015;1:67-77. [PMID: 27774250 DOI: 10.1002/osp4.13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
179 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-9693. [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 55] [Article Influence: 16.3] [Reference Citation Analysis]
180 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 11.3] [Reference Citation Analysis]
181 Toman D, Vavra P, Jelinek P, Ostruszka P, Ihnat P, Foltys A, Pelikan A, Roman J. Effect of bariatric surgery on fatty liver disease in obese patients: A prospective one year follow-up study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2021. [PMID: 33885048 DOI: 10.5507/bp.2021.021] [Reference Citation Analysis]
182 Musso G, Bo S, Cassader M, De Michieli F, Gambino R. Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr. 2013;98:895-906. [PMID: 23985808 DOI: 10.3945/ajcn.113.063792] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
183 Seko Y, Sumida Y, Tanaka S, Taketani H, Kanemasa K, Ishiba H, Okajima A, Nishimura T, Yamaguchi K, Moriguchi M. Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. Hepatol Res. 2015;45:728-738. [PMID: 25165040 DOI: 10.1111/hepr.12407] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
184 Albhaisi S, Issa D, Alkhouri N. Non-alcoholic fatty liver disease: a pandemic disease with multisystem burden. Hepatobiliary Surg Nutr 2018;7:389-91. [PMID: 30498715 DOI: 10.21037/hbsn.2018.07.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
185 Chang Y, Cho YK, Cho J, Jung H, Yun KE, Ahn J, Sohn CI, Shin H, Ryu S. Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. Am J Gastroenterol 2019;114:620-9. [DOI: 10.14309/ajg.0000000000000074] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 11.0] [Reference Citation Analysis]
186 Zhang S, Wong YT, Tang KY, Kwan HY, Su T. Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. Front Endocrinol (Lausanne) 2020;11:572729. [PMID: 33101207 DOI: 10.3389/fendo.2020.572729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
187 Lazarus JV, Anstee QM, Hagström H, Cusi K, Cortez-Pinto H, Mark HE, Roden M, Tsochatzis EA, Wong VW, Younossi ZM, Zelber-Sagi S, Romero-Gómez M, Schattenberg JM. Defining comprehensive models of care for NAFLD. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34172937 DOI: 10.1038/s41575-021-00477-7] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
188 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 41] [Article Influence: 8.1] [Reference Citation Analysis]
189 Rodriguez LA, Kanaya AM, Shiboski SC, Fernandez A, Herrington D, Ding J, Bradshaw PT. Does NAFLD mediate the relationship between obesity and type 2 diabetes risk? evidence from the multi-ethnic study of atherosclerosis (MESA). Ann Epidemiol 2021;63:15-21. [PMID: 34293421 DOI: 10.1016/j.annepidem.2021.07.005] [Reference Citation Analysis]
190 Verna EC. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. Lancet Gastroenterol Hepatol 2017;2:211-23. [PMID: 28404136 DOI: 10.1016/S2468-1253(16)30120-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 4.8] [Reference Citation Analysis]
191 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Pai RK, Yerian L, Khiyami A, Sourianarayanane A, Sargent R, Hawkins C, Dasarathy S, McCullough AJ. Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease. Dig Dis Sci. 2015;60:1825-1831. [PMID: 25708897 DOI: 10.1007/s10620-015-3529-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
192 Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020;323:1175-1183. [PMID: 32207804 DOI: 10.1001/jama.2020.2298] [Cited by in Crossref: 119] [Cited by in F6Publishing: 96] [Article Influence: 119.0] [Reference Citation Analysis]
193 Lee J, Vali Y, Boursier J, Duffin K, Verheij J, Brosnan MJ, Zwinderman K, Anstee QM, Bossuyt PM, Zafarmand MH. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis. PLoS One 2020;15:e0238717. [PMID: 32915852 DOI: 10.1371/journal.pone.0238717] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
194 Lee DH, Park SH, Huh YH, Jung Kim M, Seo HD, Ha TY, Ahn J, Jang YJ, Jung CH. Iridoids of Valeriana fauriei contribute to alleviating hepatic steatosis in obese mice by lipophagy. Biomed Pharmacother 2020;125:109950. [PMID: 32058217 DOI: 10.1016/j.biopha.2020.109950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
195 Trembling PM, Lampertico P, Parkes J, Tanwar S, Viganò M, Facchetti F, Colombo M, Rosenberg WM. Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection. J Viral Hepat 2014;21:430-8. [PMID: 24750297 DOI: 10.1111/jvh.12161] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
196 Silaghi CA, Silaghi H, Colosi HA, Craciun AE, Farcas A, Cosma DT, Hancu N, Pais R, Georgescu CE. Prevalence and predictors of non-alcoholic fatty liver disease as defined by the fatty liver index in a type 2 diabetes population. Clujul Med 2016;89:82-8. [PMID: 27004029 DOI: 10.15386/cjmed-544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
197 Jung JY, Park SK, Ryoo J, Oh C, Kang JG, Lee J, Choi J. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population: NAFLD, left ventricular diastolic dysfunction. Hepatol Res 2017;47:522-32. [DOI: 10.1111/hepr.12770] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
198 Lee J, Yoon K, Ryu S, Chang Y, Kim HR. High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men. PLoS One 2017;12:e0172666. [PMID: 28234943 DOI: 10.1371/journal.pone.0172666] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
199 Xu Z, Shi J, Yu D, Zhu L, Jia J, Fan J. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design. Adv Ther 2016;33:2069-81. [DOI: 10.1007/s12325-016-0416-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
200 Yeo SC, Ong WM, Cheng KSA, Tan CH. Weight Loss After Bariatric Surgery Predicts an Improvement in the Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score. OBES SURG 2019;29:1295-300. [DOI: 10.1007/s11695-018-03676-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
201 Wainwright P, Byrne CD. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Int J Mol Sci. 2016;17:367. [PMID: 26978356 DOI: 10.3390/ijms17030367] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 11.4] [Reference Citation Analysis]
202 Lee SH, Yun SJ, Kim DH, Jo HH, Park YS. Severity of nonalcoholic fatty liver disease on sonography and risk of coronary heart disease: Nafld Severity and Chd Risk. J Clin Ultrasound 2017;45:391-9. [DOI: 10.1002/jcu.22472] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
203 Alkhouri N, Alisi A, Okwu V, Matloob A, Ferrari F, Crudele A, De Vito R, Lopez R, Feldstein AE, Nobili V. Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Dig Dis Sci. 2015;60:2353-2359. [PMID: 25764498 DOI: 10.1007/s10620-015-3614-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
204 Akinkugbe AA, Slade GD, Barritt AS, Cole SR, Offenbacher S, Petersmann A, Kocher T, Lerch MM, Mayerle J, Völzke H, Heiss G, Holtfreter B. Periodontitis and Non-alcoholic Fatty Liver Disease, a population-based cohort investigation in the Study of Health in Pomerania. J Clin Periodontol 2017;44:1077-87. [PMID: 28804947 DOI: 10.1111/jcpe.12800] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
205 Shah RA, Kowdley KV. Serum ferritin as a biomarker for NAFLD: ready for prime time? Hepatol Int 2019;13:110-2. [PMID: 30739262 DOI: 10.1007/s12072-019-09934-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
206 Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med 2020;287:711-22. [DOI: 10.1111/joim.13035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
207 Park H, Jun DW, Park HK, Kim M. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. Ann Transl Med 2020;8:1583. [PMID: 33437782 DOI: 10.21037/atm-20-5216] [Reference Citation Analysis]
208 Martins E, Oliveira A. NAFLD and cardiovascular disease. Porto Biomed J 2018;3:e2. [PMID: 31595238 DOI: 10.1016/j.pbj.0000000000000002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
209 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
210 Temple JL, Cordero P, Li J, Nguyen V, Oben JA. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Int J Mol Sci 2016;17:E947. [PMID: 27314342 DOI: 10.3390/ijms17060947] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 15.4] [Reference Citation Analysis]
211 Phisalprapa P, Supakankunti S, Charatcharoenwitthaya P, Apisarnthanarak P, Charoensak A, Washirasaksiri C, Srivanichakorn W, Chaiyakunapruk N. Cost-effectiveness analysis of ultrasonography screening for nonalcoholic fatty liver disease in metabolic syndrome patients. Medicine (Baltimore) 2017;96:e6585. [PMID: 28445256 DOI: 10.1097/MD.0000000000006585] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
212 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
213 Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, Chung RT, Giugliano RP. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol 2018;270:245-52. [PMID: 29903515 DOI: 10.1016/j.ijcard.2018.05.087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
214 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 155] [Article Influence: 37.2] [Reference Citation Analysis]
215 Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Villa-Jimenez O, Friedman SL, Diago M, Romero-Gomez M. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology. 2016;63:1875-1887. [PMID: 26849287 DOI: 10.1002/hep.28484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
216 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 98] [Article Influence: 11.4] [Reference Citation Analysis]
217 VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15:75-85. [PMID: 27218012 DOI: 10.1007/s11901-016-0295-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 11.4] [Reference Citation Analysis]
218 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017;8:11-26. [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 35] [Article Influence: 11.3] [Reference Citation Analysis]
219 Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V; LIDO Study Group. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40:1209-1222. [PMID: 25267215 DOI: 10.1111/apt.12963] [Cited by in Crossref: 151] [Cited by in F6Publishing: 136] [Article Influence: 21.6] [Reference Citation Analysis]
220 Guo WW, Wang X, Chen XQ, Ba YY, Zhang N, Xu RR, Zhao WW, Wu X. Flavonones from Penthorum chinense Ameliorate Hepatic Steatosis by Activating the SIRT1/AMPK Pathway in HepG2 Cells. Int J Mol Sci 2018;19:E2555. [PMID: 30154382 DOI: 10.3390/ijms19092555] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
221 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep 2014;2:633-6. [PMID: 25054002 DOI: 10.3892/br.2014.309] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
222 Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5:7-13. [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
223 Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013;37:392-400. [PMID: 23278163 DOI: 10.1111/apt.12186] [Cited by in Crossref: 113] [Cited by in F6Publishing: 100] [Article Influence: 12.6] [Reference Citation Analysis]
224 Mahady SE, Gale J, Macaskill P, Craig JC, George J. Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: A cross-sectional study of 9,447 people: Elevated alanine transaminase in Australia. Journal of Gastroenterology and Hepatology 2017;32:169-76. [DOI: 10.1111/jgh.13434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
225 Williams KH, Burns K, Constantino M, Shackel NA, Prakoso E, Wong J, Wu T, George J, McCaughan GW, Twigg SM. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes.J Diabetes Complications. 2015;29:1240-1247. [PMID: 26297218 DOI: 10.1016/j.jdiacomp.2015.06.015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
226 Yamasaki Y, Nouso K, Miyahara K, Wada N, Dohi C, Morimoto Y, Kinugasa H, Takeuchi Y, Yasunaka T, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Iwasaki Y, Amano M, Nishimura S, Yamamoto K. Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis: Glycan markers for fatty liver diseases. J Gastroenterol Hepatol 2015;30:528-34. [DOI: 10.1111/jgh.12726] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
227 Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, Cha BS, Lee HC, Balkau B, Lee WY, Kim DJ. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One 2014;9:e107584. [PMID: 25216184 DOI: 10.1371/journal.pone.0107584] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
228 Zhang L, You W, Zhang H, Peng R, Zhu Q, Yao A, Li X, Zhou Y, Wang X, Pu L, Wu J. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol. 2015;30:821-829. [PMID: 25641744 DOI: 10.1111/jgh.12889] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
229 Solfrizzi V, Scafato E, Custodero C, Loparco F, Ciavarella A, Panza F, Seripa D, Imbimbo BP, Lozupone M, Napoli N, Piazzolla G, Galluzzo L, Gandin C, Baldereschi M, Di Carlo A, Inzitari D, Pilotto A, Sabbà C; Italian Longitudinal Study on Aging Working Group. Liver fibrosis score, physical frailty, and the risk of dementia in older adults: The Italian Longitudinal Study on Aging. Alzheimers Dement (N Y) 2020;6:e12065. [PMID: 32864415 DOI: 10.1002/trc2.12065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Santos RD, Valenti L, Romeo S. Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis 2019;282:110-20. [PMID: 30731283 DOI: 10.1016/j.atherosclerosis.2019.01.029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 18.0] [Reference Citation Analysis]
231 Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013;62:352-60. [DOI: 10.1016/j.metabol.2012.08.005] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 11.3] [Reference Citation Analysis]
232 Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: an update. World J Gastroenterol. 2014;20:9050-9054. [PMID: 25083078 DOI: 10.3748/wjg.v20.i27.9050] [Cited by in F6Publishing: 38] [Reference Citation Analysis]
233 Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015;5:147-158. [PMID: 26155043 DOI: 10.1016/j.jceh.2015.02.002] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 11.7] [Reference Citation Analysis]
234 Kartoun U. Toward an accelerated adoption of data-driven findings in medicine: Research, skepticism, and the need to speed up public visibility of data-driven findings. Med Health Care and Philos 2019;22:153-7. [DOI: 10.1007/s11019-018-9845-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
235 Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2121-30.e1-2. [PMID: 24846279 DOI: 10.1016/j.cgh.2014.05.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
236 Chang Y, Cho J, Cho YK, Cho A, Hong YS, Zhao D, Ahn J, Sohn CI, Shin H, Guallar E, Ryu S. Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases. Clinical Gastroenterology and Hepatology 2020;18:205-215.e7. [DOI: 10.1016/j.cgh.2019.05.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
237 Caballería L, Arteaga I, Pera G, Rodríguez L, Alumà A, Auladell MA, Torán P. [Risk factors associated with non-alcoholic fatty liver disease: a case-control study]. Med Clin (Barc) 2013;141:233-9. [PMID: 23601740 DOI: 10.1016/j.medcli.2012.11.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
238 Reja M, Patel R, Pioppo L, Tawadros A, Bhurwal A, Marino D, Rustgi V. Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic Steatohepatitis. J Clin Gastroenterol 2021;55:433-8. [PMID: 32740097 DOI: 10.1097/MCG.0000000000001389] [Reference Citation Analysis]
239 Bo S, Musso G, Gambino R, Villois P, Gentile L, Durazzo M, Cavallo-perin P, Cassader M. Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort. The American Journal of Clinical Nutrition 2012;96:962-9. [DOI: 10.3945/ajcn.112.040006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
240 Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017;177:633-640. [PMID: 28241279 DOI: 10.1001/jamainternmed.2016.9607] [Cited by in Crossref: 151] [Cited by in F6Publishing: 122] [Article Influence: 37.8] [Reference Citation Analysis]
241 Williams KH, Sullivan DR, Veillard AS, O'brien R, George J, Jenkins AJ, Young S, Ehnholm C, Duffield A, Twigg SM, Keech AC. Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabet Med 2016;33:356-64. [DOI: 10.1111/dme.12972] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
242 Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, Papatheodoridis G, Combet E. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;83:120-127. [PMID: 29409822 DOI: 10.1016/j.metabol.2018.01.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 9.7] [Reference Citation Analysis]
243 Ostovaneh MR, Ambale-Venkatesh B, Fuji T, Bakhshi H, Shah R, Murthy VL, Tracy RP, Guallar E, Wu CO, Bluemke DA, Lima JAC. Association of Liver Fibrosis With Cardiovascular Diseases in the General Population: The Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging 2018;11:e007241. [PMID: 29523555 DOI: 10.1161/CIRCIMAGING.117.007241] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
244 Fuchs M. New Medical Treatment Strategies for Nonalcoholic Steatohepatitis. Curr Treat Options Gastro 2015;13:259-73. [DOI: 10.1007/s11938-015-0053-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
245 Green CJ, Marjot T, Tomlinson JW, Hodson L. Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis? Diabetes Obes Metab 2019;21:749-60. [DOI: 10.1111/dom.13592] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
246 Mazzolini G, Atorrasagasti C, Onorato A, Peixoto E, Schlattjan M, Sowa JP, Sydor S, Gerken G, Canbay A. SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease. Sci Rep 2018;8:725. [PMID: 29335425 DOI: 10.1038/s41598-017-18981-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
247 Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, Kaul I, Sowa J, Canbay A, Töx U, Steffen HM. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One 2013;8:e58360. [PMID: 23555578 DOI: 10.1371/journal.pone.0058360] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
248 Kim HM, Kim BS, Cho YK, Kim BI, Sohn CI, Jeon WK, Kim HJ, Park DI, Park JH, Joo KJ. Elevated red cell distribution width is associated with advanced fibrosis in NAFLD. Clin Mol Hepatol. 2013;19:258-265. [PMID: 24133663 DOI: 10.3350/cmh.2013.19.3.258] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
249 Papandreou D, Andreou E. Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol. 2015;7:575-582. [PMID: 25848481 DOI: 10.4254/wjh.v7.i3.575] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
250 Monserrat-Mesquida M, Quetglas-Llabrés M, Abbate M, Montemayor S, Mascaró CM, Casares M, Tejada S, Abete I, Zulet MA, Tur JA, Martínez JA, Sureda A. Oxidative Stress and Pro-Inflammatory Status in Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel) 2020;9:E759. [PMID: 32824349 DOI: 10.3390/antiox9080759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
251 Ciardullo S, Muraca E, Perra S, Bianconi E, Zerbini F, Oltolini A, Cannistraci R, Parmeggiani P, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res Care. 2020;8. [PMID: 32049637 DOI: 10.1136/bmjdrc-2019-000904] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
252 Sinn DH, Kang D, Chang Y, Ryu S, Gu S, Kim H, Seong D, Cho SJ, Yi BK, Park HD, Paik SW, Song YB, Lazo M, Lima JA, Guallar E, Cho J, Gwak GY. Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study. Gut. 2017;66:323-329. [PMID: 27599521 DOI: 10.1136/gutjnl-2016-311854] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 13.6] [Reference Citation Analysis]
253 Bertol FS, Araujo B, Jorge BB, Rinaldi N, De Carli LA, Tovo CV. Role of micronutrients in staging of nonalcoholic fatty liver disease: A retrospective cross-sectional study. World J Gastrointest Surg 2020;12:269-76. [PMID: 32774765 DOI: 10.4240/wjgs.v12.i6.269] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
254 Stankovic Z. Four-dimensional flow magnetic resonance imaging in cirrhosis. World J Gastroenterol. 2016;22:89-102. [PMID: 26755862 DOI: 10.3748/wjg.v22.i1.89] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
255 Petta S, Vanni E, Bugianesi E, Di Marco V, Cammà C, Cabibi D, Mezzabotta L, Craxì A. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2015;35:1566-1573. [PMID: 24798049 DOI: 10.1111/liv.12584] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
256 Bedossa P, Patel K. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1811-1822.e4. [PMID: 27003601 DOI: 10.1053/j.gastro.2016.03.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
257 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 49] [Article Influence: 20.3] [Reference Citation Analysis]
258 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9:715-732. [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 290] [Cited by in F6Publishing: 226] [Article Influence: 72.5] [Reference Citation Analysis]
259 Musso G, Saba F, Cassader M, Paschetta E, De Michieli F, Pinach S, Framarin L, Berrutti M, Leone N, Parente R, Ayoubi Khajekini MT, Zarovska A, Gambino R. Angiotensin II Type 1 Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hypertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation. Am J Gastroenterol 2019;114:607-19. [PMID: 30920415 DOI: 10.14309/ajg.0000000000000154] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
260 Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-54. [DOI: 10.1002/hep.27368] [Cited by in Crossref: 1010] [Cited by in F6Publishing: 850] [Article Influence: 168.3] [Reference Citation Analysis]
261 Schuster-Gaul S, Geisler LJ, McGeough MD, Johnson CD, Zagorska A, Li L, Wree A, Barry V, Mikaelian I, Jih LJ, Papouchado BG, Budas G, Hoffman HM, Feldstein AE. ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model. JCI Insight 2020;5:123294. [PMID: 31996485 DOI: 10.1172/jci.insight.123294] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
262 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, Sourianarayanane A, Khiyami A, Yerian L, Pai RK, Dasarathy S, McCullough AJ. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clin. 2015;3:141-145. [PMID: 26675585 DOI: 10.1016/j.bbacli.2014.09.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
263 Khan MY, Mihali AB, Rawala MS, Aslam A, Siddiqui WJ. The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:703-15. [PMID: 31009401 DOI: 10.1097/MEG.0000000000001371] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
264 De Vincentis A, Antonelli-Incalzi R, Picardi A, Vespasiani-Gentilucci U. Association between clinical scores of liver fibrosis and adverse non-hepatic outcomes: The key in the holistic vision of the patient. J Diabetes Complications 2021;35:107891. [PMID: 33642147 DOI: 10.1016/j.jdiacomp.2021.107891] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Strnad P, Paschke S, Jang KH, Ku NO. Keratins: markers and modulators of liver disease. Curr Opin Gastroenterol. 2012;28:209-216. [PMID: 22450891 DOI: 10.1097/mog.0b013e3283525cb8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
266 Anderson EJ, Vistoli G, Katunga LA, Funai K, Regazzoni L, Monroe TB, Gilardoni E, Cannizzaro L, Colzani M, De Maddis D, Rossoni G, Canevotti R, Gagliardi S, Carini M, Aldini G. A carnosine analog mitigates metabolic disorders of obesity by reducing carbonyl stress. J Clin Invest 2018;128:5280-93. [PMID: 30226473 DOI: 10.1172/JCI94307] [Cited by in Crossref: 46] [Cited by in F6Publishing: 22] [Article Influence: 15.3] [Reference Citation Analysis]
267 Shaheen AA, Riazi K, Medellin A, Bhayana D, Kaplan GG, Jiang J, Park R, Schaufert W, Burak KW, Sargious M, Swain MG. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020;8:E370-6. [PMID: 32414883 DOI: 10.9778/cmajo.20200009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
268 Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46:1074-1087. [PMID: 26785389 DOI: 10.1111/hepr.12656] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 14.8] [Reference Citation Analysis]
269 Sanal MG. Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol. 2015;21:3223-3231. [PMID: 25805928 DOI: 10.3748/wjg.v21.i11.3223] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
270 Mazzotti A, Caletti MT, Marchignoli F, Forlani G, Marchesini G. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Dig Liver Dis 2017;49:235-40. [PMID: 28089623 DOI: 10.1016/j.dld.2016.12.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
271 Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, Rametta R, Fracanzani AL, Mozzi E, Craxì A. The UCP2 -866 G& gt; A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int. 2015;35:1574-1580. [PMID: 25351290 DOI: 10.1111/liv.12707] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
272 Alkhouri N, McCullough AJ. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8:661-668. [PMID: 24683373 DOI: 10.1016/s0016-5085(10)62097-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
273 Musso G, Cassader M, Bo S, De Michieli F, Gambino R. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 2013;62:1109-20. [PMID: 23274901 DOI: 10.2337/db12-0858] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
274 Góralska J, Raźny U, Polus A, Dziewońska A, Gruca A, Zdzienicka A, Dembińska-Kieć A, Solnica B, Micek A, Kapusta M, Słowińska-Solnica K, Malczewska-Malec M. Enhanced GIP Secretion in Obesity Is Associated with Biochemical Alteration and miRNA Contribution to the Development of Liver Steatosis. Nutrients 2020;12:E476. [PMID: 32069846 DOI: 10.3390/nu12020476] [Reference Citation Analysis]
275 Wu M, Fang Q, Zou S, Zhu Y, Lu W, Du X, Shi B. Influencing factors for hepatic fat accumulation in patients with type 2 diabetes mellitus. WJCC 2021;9:7717-28. [DOI: 10.12998/wjcc.v9.i26.7717] [Reference Citation Analysis]
276 Tai FW, Syn WK, Alazawi W. Practical approach to non-alcoholic fatty liver disease in patients with diabetes. Diabet Med. 2015; Feb 12. [Epub ahead of print]. [PMID: 25683343 DOI: 10.1111/dme.12725] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
277 van der Voort EA, Koehler EM, Dowlatshahi EA, Hofman A, Stricker BH, Janssen HL, Schouten JN, Nijsten T. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol. 2014;70:517-524. [PMID: 24373781 DOI: 10.1016/j.jaad.2013.10.044] [Cited by in Crossref: 85] [Cited by in F6Publishing: 68] [Article Influence: 10.6] [Reference Citation Analysis]
278 Stättermayer AF, Traussnigg S, Aigner E, Kienbacher C, Huber-schönauer U, Steindl-munda P, Stadlmayr A, Wrba F, Trauner M, Datz C, Ferenci P. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. Journal of Trace Elements in Medicine and Biology 2017;39:100-7. [DOI: 10.1016/j.jtemb.2016.08.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
279 VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, Rinella ME, Shah SJ. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology. 2015;62:773-783. [PMID: 25914296 DOI: 10.1002/hep.27869] [Cited by in Crossref: 133] [Cited by in F6Publishing: 111] [Article Influence: 22.2] [Reference Citation Analysis]
280 Le L, Kullar R, Saleh HM, Saab S. Preferred Noninvasive Testing for Nonalcoholic Steatohepatitis. Dig Dis Sci 2020;65:3719-25. [PMID: 32671584 DOI: 10.1007/s10620-020-06382-4] [Reference Citation Analysis]
281 Peng TC, Kao TW, Wu LW, Chen YJ, Chang YW, Wang CC, Tsao YT, Chen WL. Association Between Pulmonary Function and Nonalcoholic Fatty Liver Disease in the NHANES III Study. Medicine (Baltimore) 2015;94:e907. [PMID: 26020401 DOI: 10.1097/MD.0000000000000907] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
282 Karahashi M, Hirata-Hanta Y, Kawabata K, Tsutsumi D, Kametani M, Takamatsu N, Sakamoto T, Yamazaki T, Asano S, Mitsumoto A, Kawashima Y, Kudo N. Abnormalities in the Metabolism of Fatty Acids and Triacylglycerols in the Liver of the Goto-Kakizaki Rat: A Model for Non-Obese Type 2 Diabetes. Lipids 2016;51:955-71. [PMID: 27372943 DOI: 10.1007/s11745-016-4171-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
283 Pallotta N, Filardi T, Carnovale A, Nieddu L, Mariani P, Vincoli G, Lenzi A, Morano S. Two-hour postload glycemia is associated to an increased risk of NAFLD in healthy subjects with family history of type 2 diabetes: a case control study. Endocrine 2017;57:352-5. [PMID: 27422790 DOI: 10.1007/s12020-016-1008-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
284 Fallatah HI, Akbar HO, Fallatah AM. Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease. Hepat Mon 2016;16:e38346. [PMID: 27642348 DOI: 10.5812/hepatmon.38346] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
285 Hydes T, Buchanan R, Kennedy OJ, Fraser S, Parkes J, Roderick P. Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease. BMJ Open 2020;10:e040970. [PMID: 32988952 DOI: 10.1136/bmjopen-2020-040970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
286 Muangpaisarn P, Jampoka K, Payungporn S, Wisedopas N, Bunchorntavakul C, Tangkijvanich P, Treeprasertsuk S. Serum microRNA-34a is potential biomarker for inflammation in nonalcoholic fatty liver disease. Asian Biomedicine 2017;10:163-71. [DOI: 10.5372/1905-7415.1002.478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
287 Konerman MA, Walden P, Joseph M, Jackson EA, Lok AS, Rubenfire M. Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;49:296-307. [PMID: 30561027 DOI: 10.1111/apt.15063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
288 Bakulin IG, Sandler YG, Vinnitskaya EV, Keiyan VA, Rodionova SV, Rotin DL. [Diabetes mellitus and nonalcoholic fatty liver disease: The verges of contingency]. Ter Arkh 2017;89:59-65. [PMID: 28281517 DOI: 10.17116/terarkh201789259-65] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
289 Hecht L, Weiss R. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Obese Children. Curr Diab Rep 2014;14. [DOI: 10.1007/s11892-013-0448-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
290 Bhatt HB, Smith RJ. Fatty liver disease in diabetes mellitus. Hepatobiliary Surg Nutr. 2015;4:101-108. [PMID: 26005676 DOI: 10.3978/j.issn.2304-3881.2015.01.03] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
291 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
292 VanWagner LB, Ning H, Allen NB, Siddique J, Carson AP, Bancks MP, Lewis CE, Carr JJ, Speliotes E, Terrault NA, Rinella ME, Vos MB, Lloyd-Jones DM. Twenty-five-year trajectories of insulin resistance and pancreatic β-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int 2018;38:2069-81. [PMID: 29608255 DOI: 10.1111/liv.13747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
293 Esterson YB, Grimaldi GM. Radiologic Imaging in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018;22:93-108. [PMID: 29128063 DOI: 10.1016/j.cld.2017.08.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
294 Jensen T, Niwa K, Hisatome I, Kanbay M, Andres-Hernando A, Roncal-Jimenez CA, Sato Y, Garcia G, Ohno M, Lanaspa MA, Johnson RJ, Kuwabara M. Increased Serum Uric Acid over five years is a Risk Factor for Developing Fatty Liver. Sci Rep. 2018;8:11735. [PMID: 30082907 DOI: 10.1038/s41598-018-30267-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
295 Akinkugbe AA, Barritt AS, Cai J, Offenbacher S, Thyagarajan B, Khambaty T, Singer R, Kallwitz E, Heiss G, Slade GD. Periodontitis and prevalence of elevated aminotransferases in the Hispanic Community Health Study/Study of Latinos. J Periodontol 2018;89:949-58. [PMID: 29717494 DOI: 10.1002/JPER.17-0579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
296 Villela-Nogueira CA, Leite NC, Cardoso CR, Salles GF. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? Int J Mol Sci 2016;17:E460. [PMID: 27104526 DOI: 10.3390/ijms17040460] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
297 Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol 2016;22:7236-51. [PMID: 27621571 DOI: 10.3748/wjg.v22.i32.7236] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 84] [Article Influence: 25.0] [Reference Citation Analysis]
298 Guaraldi G, Lonardo A, Maia L, Palella FJ Jr. Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver. AIDS 2017;31 Suppl 2:S147-56. [PMID: 28471945 DOI: 10.1097/QAD.0000000000001483] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 6.7] [Reference Citation Analysis]
299 Machado MV, Cortez-Pinto H. Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol. 2014;8:487-500. [PMID: 24665862 DOI: 10.1586/17474124.2014.903798] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
300 Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, Romeo S, Valenti L. PNPLA3 I148M polymorphism and progressive liver disease. World J Gastroenterol 2013;19:6969-78. [PMID: 24222941 DOI: 10.3748/wjg.v19.i41.6969] [Cited by in CrossRef: 135] [Cited by in F6Publishing: 126] [Article Influence: 19.3] [Reference Citation Analysis]
301 Lückhoff HK, Kruger FC, Kotze MJ. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol. 2015;7:1192-1208. [PMID: 26019735 DOI: 10.4254/wjh.v7.i9.1192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
302 Spinosa M, Stine JG. Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State? Curr Pharm Des 2020;26:1036-44. [PMID: 32003679 DOI: 10.2174/1381612826666200131101553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
303 Zhang ZQ, Wang GS, Kang KF, Wu GB, Wang P. Nomogram for hepatic steatosis: A simple and economical diagnostic tool for massive screening. Dig Liver Dis 2016;48:914-20. [PMID: 27246795 DOI: 10.1016/j.dld.2016.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
304 Kanerva N, Sandboge S, Kaartinen NE, Männistö S, Eriksson JG. Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr. 2014;100:1133-1138. [PMID: 25099548 DOI: 10.3945/ajcn.114.086074] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
305 Konstantopoulos P, Doulamis IP, Tzani A, Korou ML, Agapitos E, Vlachos IS, Pergialiotis V, Verikokos C, Mastorakos G, Katsilambros NL, Perrea DN. Metabolic effects of Crocus sativus and protective action against non-alcoholic fatty liver disease in diabetic rats. Biomed Rep 2017;6:513-8. [PMID: 28529733 DOI: 10.3892/br.2017.884] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
306 Yu Q, Jiang Z, Zhang L. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease. Pharmacol Ther 2018;190:81-90. [PMID: 29684468 DOI: 10.1016/j.pharmthera.2018.04.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
307 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
308 Agrawal S, Duseja A, Aggarwal A, Das A, Mehta M, Dhiman RK, Chawla Y. Obstructive sleep apnea is an important predictor of hepatic fibrosis in patients with nonalcoholic fatty liver disease in a tertiary care center. Hepatol Int. 2015;9:283-291. [PMID: 25788200 DOI: 10.1007/s12072-015-9615-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
309 Oancea CN, Butaru AE, Streba CT, Pirici D, Rogoveanu I, Diculescu MM, Gheonea DI. Global hepatitis C elimination: history, evolution, revolutionary changes and barriers to overcome. Rom J Morphol Embryol 2020;61:643-53. [PMID: 33817705 DOI: 10.47162/RJME.61.3.02] [Reference Citation Analysis]
310 Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:1388-9. [PMID: 27038241 DOI: 10.1002/hep.28584] [Cited by in Crossref: 43] [Cited by in F6Publishing: 31] [Article Influence: 8.6] [Reference Citation Analysis]
311 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
312 Hui ST, Kurt Z, Tuominen I, Norheim F, C Davis R, Pan C, Dirks DL, Magyar CE, French SW, Chella Krishnan K, Sabir S, Campos-Pérez F, Méndez-Sánchez N, Macías-Kauffer L, León-Mimila P, Canizales-Quinteros S, Yang X, Beaven SW, Huertas-Vazquez A, Lusis AJ. The Genetic Architecture of Diet-Induced Hepatic Fibrosis in Mice. Hepatology 2018;68:2182-96. [PMID: 29907965 DOI: 10.1002/hep.30113] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
313 Zsóri G, Illés D, Ivány E, Kosár K, Holzinger G, Tajti M, Pálinkás E, Szabovik G, Nagy A, Palkó A, Czakó L. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metab Syndr Relat Disord 2019;17:289-95. [PMID: 31013454 DOI: 10.1089/met.2018.0086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
314 Mumtaz S, Schomaker N, Von Roenn N. Pro: Noninvasive Imaging Has Replaced Biopsy as the Gold Standard in the Evaluation of Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2019;13:111-3. [PMID: 31061704 DOI: 10.1002/cld.750] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
315 Lai LL, Vethakkan SR, Nik Mustapha NR, Mahadeva S, Chan WK. Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus. Dig Dis Sci 2020;65:623-31. [PMID: 30684076 DOI: 10.1007/s10620-019-5477-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 24.0] [Reference Citation Analysis]
316 Olubamwo OO, Virtanen JK, Pihlajamaki J, Tuomainen TP. Association of fatty liver index with risk of incident type 2 diabetes by metabolic syndrome status in an Eastern Finland male cohort: a prospective study. BMJ Open 2019;9:e026949. [PMID: 31278098 DOI: 10.1136/bmjopen-2018-026949] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
317 Yamada K, Mizukoshi E, Seike T, Horii R, Kitahara M, Sunagozaka H, Arai K, Yamashita T, Honda M, Kaneko S. Light alcohol consumption has the potential to suppress hepatocellular injury and liver fibrosis in non-alcoholic fatty liver disease. PLoS One 2018;13:e0191026. [PMID: 29342182 DOI: 10.1371/journal.pone.0191026] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
318 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
319 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26:802-809. [PMID: 21198831 DOI: 10.1111/j.1440-1746.2010.06612.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 6.5] [Reference Citation Analysis]
320 Rosso C, Caviglia GP, Abate ML, Vanni E, Mezzabotta L, Touscoz GA, Olivero A, Marengo A, Rizzetto M, Bugianesi E, Smedile A. Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis. Dig Liver Dis 2016;48:55-61. [PMID: 26514735 DOI: 10.1016/j.dld.2015.09.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
321 Kwak MS, Kim D. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity. Korean J Intern Med 2018;33:64-74. [PMID: 29202557 DOI: 10.3904/kjim.2017.343] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
322 Acín S, Muñoz DL, Guillen A, Soscue D, Castaño A, Echeverri F, Balcazar N. Triterpene-enriched fractions from Eucalyptus tereticornis ameliorate metabolic alterations in a mouse model of diet-induced obesity. J Ethnopharmacol 2021;265:113298. [PMID: 32860892 DOI: 10.1016/j.jep.2020.113298] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
323 Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis. Int J Endocrinol 2013;2013:124958. [PMID: 23690766 DOI: 10.1155/2013/124958] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
324 Thong VD, Quynh BTH. Correlation of Serum Transaminase Levels with Liver Fibrosis Assessed by Transient Elastography in Vietnamese Patients with Nonalcoholic Fatty Liver Disease. Int J Gen Med 2021;14:1349-55. [PMID: 33889015 DOI: 10.2147/IJGM.S309311] [Reference Citation Analysis]
325 Musso G. Non-alcoholic fatty liver, adipose tissue, and the bone: a new triumvirate on the block. Endocrine 2012;42:237-9. [PMID: 22801991 DOI: 10.1007/s12020-012-9748-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
326 Francque SM, Verrijken A, Mertens I, Hubens G, Van Marck E, Pelckmans P, Michielsen P, Van Gaal L. Noninvasive assessment of nonalcoholic fatty liver disease in obese or overweight patients. Clin Gastroenterol Hepatol. 2012;10:1162-1168; quiz e87. [PMID: 22796457 DOI: 10.1016/j.cgh.2012.06.019] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
327 Jun DW, Kim SG, Park SH, Jin SY, Lee JS, Lee JW, Kim MY, Choi DH, Cho YK, Yeon JE, Sohn JH; Korean NAFLD study group (KNSG). External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients. J Gastroenterol Hepatol. 2017;32:1094-1099. [PMID: 27859583 DOI: 10.1111/jgh.13648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
328 Zuo Y, Sarkar S, Corwin MT, Olson K, Badawi RD, Wang G. Structural and practical identifiability of dual-input kinetic modeling in dynamic PET of liver inflammation. Phys Med Biol 2019;64:175023. [PMID: 31051490 DOI: 10.1088/1361-6560/ab1f29] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
329 Targher G, Marchesini G, Byrne CD. Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? Diabetes Metab. 2016;42:142-156. [PMID: 27142870 DOI: 10.1016/j.diabet.2016.04.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 10.2] [Reference Citation Analysis]
330 Corey KE, Rinella ME. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis. Dig Dis Sci 2016;61:1387-97. [PMID: 26942734 DOI: 10.1007/s10620-016-4083-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
331 Arab JP, Hernández-rocha C, Morales C, Vargas JI, Solís N, Pizarro M, Robles C, Sandoval D, Ponthus S, Benítez C, Barrera F, Soza A, Riquelme A, Arrese M. Fragmento sérico de citoqueratina-18 como marcador no invasivo de esteatohepatitis no alcohólica en población chilena. Gastroenterología y Hepatología 2017;40:388-94. [DOI: 10.1016/j.gastrohep.2017.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
332 Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, Lee KL, Kim W. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66:123-131. [PMID: 27599824 DOI: 10.1016/j.jhep.2016.08.019] [Cited by in Crossref: 163] [Cited by in F6Publishing: 135] [Article Influence: 32.6] [Reference Citation Analysis]
333 Wang G, Corwin MT, Olson KA, Badawi RD, Sarkar S. Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol. 2018;63:155004. [PMID: 29847315 DOI: 10.1088/1361-6560/aac8cb] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
334 de Lédinghen V, Wong VW, Vergniol J, Wong GL, Foucher J, Chu SH, Le Bail B, Choi PC, Chermak F, Yiu KK, Merrouche W, Chan HL. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol 2012;56:833-9. [PMID: 22173167 DOI: 10.1016/j.jhep.2011.10.017] [Cited by in Crossref: 166] [Cited by in F6Publishing: 134] [Article Influence: 16.6] [Reference Citation Analysis]
335 Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung H, Yun KE, Shin H, Ryu S. Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study: Hepatology. Hepatology 2019;69:64-75. [DOI: 10.1002/hep.30170] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 16.0] [Reference Citation Analysis]
336 Moret A, Boursier J, Houssel Debry P, Riou J, Crouan A, Dubois M, Michalak Provost S, Aubé C, Paisant A. Evaluation of the Hepatorenal B-Mode Ratio and the "Controlled Attenuation Parameter" for the Detection and Grading of Steatosis. Ultraschall Med 2020. [PMID: 32992377 DOI: 10.1055/a-1233-2290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
337 Lee C, Kim J, Jung Y. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells 2019;8:E1259. [PMID: 31619023 DOI: 10.3390/cells8101259] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
338 Kogachi S, Noureddin M. Noninvasive Evaluation for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Clin Ther 2021;43:455-72. [PMID: 33581876 DOI: 10.1016/j.clinthera.2021.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
339 Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol. 2015;21:6820-6834. [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 73] [Article Influence: 17.6] [Reference Citation Analysis]
340 Im HJ, Hwang SJ, Lee JS, Lee SB, Kang JY, Son CG. Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model. Nutrients 2020;12:E2433. [PMID: 32823613 DOI: 10.3390/nu12082433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
341 Elias S, Wisam S, Luai A, Massad B, Nimer A. Lipotoxicity in Obesity: Benefit of Olive Oil. Adv Exp Med Biol 2017;960:607-17. [PMID: 28585218 DOI: 10.1007/978-3-319-48382-5_26] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
342 Lee YS, Lee HS, Chang SW, Lee CU, Kim JS, Jung YK, Kim JH, Seo YS, Yim HJ, Lee CH, Woo SU, Seo JH, Yeon JE, Um SH, Byun KS. Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery. Medicine (Baltimore) 2019;98:e17277. [PMID: 31574842 DOI: 10.1097/MD.0000000000017277] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
343 Avramovski P, Avramovska M, Nikleski Z, Ilkovska B, Sotiroski K, Sikole E. The predictive value of the hepatorenal index for detection of impaired glucose metabolism in patients with non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:50-9. [PMID: 32185691 DOI: 10.1007/s12664-019-01009-7] [Reference Citation Analysis]
344 Chiriac S, Stanciu C, Girleanu I, Cojocariu C, Sfarti C, Singeap AM, Cuciureanu T, Huiban L, Muzica CM, Zenovia S, Nastasa R, Trifan A. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter. Can J Gastroenterol Hepatol 2021;2021:6696857. [PMID: 33505944 DOI: 10.1155/2021/6696857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
345 Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, Hwang JP, Barranco-Fragoso B, Cordova-Gallardo J. New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. Int J Mol Sci. 2018;19. [PMID: 30011790 DOI: 10.3390/ijms19072034] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 20.3] [Reference Citation Analysis]
346 Bedossa P;  FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565-575. [PMID: 24753132 DOI: 10.1002/hep.27173] [Cited by in Crossref: 285] [Cited by in F6Publishing: 238] [Article Influence: 40.7] [Reference Citation Analysis]
347 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014;20:475-85. [PMID: 24574716 DOI: 10.3748/wjg.v20.i2.475] [Cited by in CrossRef: 240] [Cited by in F6Publishing: 202] [Article Influence: 34.3] [Reference Citation Analysis]
348 He T, Zhang X, Hao J, Ding S. Phosphatase and Tensin Homolog in Non-neoplastic Digestive Disease: More Than Just Tumor Suppressor. Front Physiol 2021;12:684529. [PMID: 34140896 DOI: 10.3389/fphys.2021.684529] [Reference Citation Analysis]
349 Xanthakos SA, Lavine JE, Yates KP, Schwimmer JB, Molleston JP, Rosenthal P, Murray KF, Vos MB, Jain AK, Scheimann AO, Miloh T, Fishbein M, Behling CA, Brunt EM, Sanyal AJ, Tonascia J; NASH Clinical Research Network. Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. Gastroenterology 2020;159:1731-1751.e10. [PMID: 32712103 DOI: 10.1053/j.gastro.2020.07.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
350 Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20:475-485. [PMID: 24574716 DOI: 10.3748/wpg.v20.i2.475] [Reference Citation Analysis]
351 Hirono H, Watanabe K, Hasegawa K, Kohno M, Terai S, Ohkoshi S. Impact of continuous positive airway pressure therapy for nonalcoholic fatty liver disease in patients with obstructive sleep apnea. World J Clin Cases 2021;9:5112-25. [PMID: 34307562 DOI: 10.12998/wjcc.v9.i19.5112] [Reference Citation Analysis]
352 Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, Ortiz-Lopez C, Hecht J, Feldstein AE, Webb A, Louden C, Goros M, Tio F. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167-174. [PMID: 23973932 DOI: 10.1016/j.jhep.2013.07.042] [Cited by in Crossref: 154] [Cited by in F6Publishing: 128] [Article Influence: 19.3] [Reference Citation Analysis]
353 Lee AK, Kim DH, Bang E, Choi YJ, Chung HY. β-Hydroxybutyrate Suppresses Lipid Accumulation in Aged Liver through GPR109A-mediated Signaling. Aging Dis 2020;11:777-90. [PMID: 32765945 DOI: 10.14336/AD.2019.0926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
354 Rajput R, Ahlawat P. Prevalence and predictors of non-alcoholic fatty liver disease in prediabetes. Diabetes Metab Syndr 2019;13:2957-60. [PMID: 31425963 DOI: 10.1016/j.dsx.2019.07.060] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
355 Jayaraman T, Lee YY, Chan WK, Mahadeva S. Epidemiological differences of common liver conditions between Asia and the West. JGH Open. 2020;4:332-339. [PMID: 32514433 DOI: 10.1002/jgh3.12275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
356 Vieira Barbosa J, Lai M. Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting. Hepatol Commun 2021;5:158-67. [PMID: 33553966 DOI: 10.1002/hep4.1618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
357 Gawrieh S, Chalasani N. NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? Gastroenterology 2013;145:717-9. [PMID: 23973850 DOI: 10.1053/j.gastro.2013.08.025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
358 Musso G, Cipolla U, Cassader M, Pinach S, Saba F, De Michieli F, Paschetta E, Bongiovanni D, Framarin L, Leone N, Berrutti M, Rosina F, Corvisieri S, Molinaro F, Sircana A, Gambino R. TM6SF2 rs58542926 variant affects postprandial lipoprotein metabolism and glucose homeostasis in NAFLD. J Lipid Res 2017;58:1221-9. [PMID: 28242789 DOI: 10.1194/jlr.M075028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
359 Jun DW. Practice Guideline for the Diagnosis and Management of Non-alcoholic Fatty Liver Disease. Korean J Gastroenterol 2012;60:64. [DOI: 10.4166/kjg.2012.60.1.64] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
360 Anstee QM, Jaques B, Hudson M, Reeves HL. Reply to “Hepatocellular carcinoma and the Newcastle-upon-Tyne area”. Journal of Hepatology 2014;60:1330-1. [DOI: 10.1016/j.jhep.2014.02.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
361 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.00] [Reference Citation Analysis]
362 Bonafini S, Tagetti A, Gaudino R, Cavarzere P, Montagnana M, Danese E, Benati M, Ramaroli DA, Raimondi S, Giontella A, Mantovani A, Donato A, Dalbeni A, Minuz P, Antoniazzi F, Maffeis C, Fava C. Individual fatty acids in erythrocyte membranes are associated with several features of the metabolic syndrome in obese children. Eur J Nutr 2019;58:731-42. [PMID: 29594475 DOI: 10.1007/s00394-018-1677-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
363 Kobyliak N, Abenavoli L, Falalyeyeva T, Beregova T. Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease. Ann Hepatol. 2018;17:153-161. [PMID: 29311399 DOI: 10.5604/01.3001.0010.7547] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 8.7] [Reference Citation Analysis]
364 Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425-443. [PMID: 27091791 DOI: 10.1016/j.jhep.2016.04.005] [Cited by in Crossref: 190] [Cited by in F6Publishing: 165] [Article Influence: 38.0] [Reference Citation Analysis]
365 Ekta, Gupta M, Kaur A, Singh TG, Bedi O. Pathobiological and molecular connections involved in the high fructose and high fat diet induced diabetes associated nonalcoholic fatty liver disease. Inflamm Res 2020;69:851-67. [DOI: 10.1007/s00011-020-01373-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
366 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 715] [Article Influence: 153.0] [Reference Citation Analysis]
367 Chang Y, Jung H, Yun KE, Cho J, Ahn J, Chung EC, Shin H, Ryu S. Metabolically healthy obesity is associated with an increased risk of diabetes independently of nonalcoholic fatty liver disease: Obesity, Fatty Liver, and Incident Diabetes. Obesity 2016;24:1996-2003. [DOI: 10.1002/oby.21580] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
368 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 47.0] [Reference Citation Analysis]
369 Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, Roverato A, Guaraldi G, Lonardo A. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31:936-944. [PMID: 26667191 DOI: 10.1111/jgh.13264] [Cited by in Crossref: 318] [Cited by in F6Publishing: 276] [Article Influence: 79.5] [Reference Citation Analysis]
370 Boursier J, Rousselet M, Aubé C, Calès P. Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics 2012;6:381-94. [DOI: 10.1517/17530059.2012.691878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
371 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 18.5] [Reference Citation Analysis]
372 Ranjit S, Dvornikov A, Dobrinskikh E, Wang X, Luo Y, Levi M, Gratton E. Measuring the effect of a Western diet on liver tissue architecture by FLIM autofluorescence and harmonic generation microscopy. Biomed Opt Express 2017;8:3143-54. [PMID: 28717559 DOI: 10.1364/BOE.8.003143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
373 Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol. 2012;23:345-352. [PMID: 22617751 DOI: 10.1097/MOL.0b013e3283541cfc] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
374 Yoshihisa A, Sato Y, Yokokawa T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Saitoh SI, Takeishi Y. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail 2018;5:262-70. [PMID: 28967709 DOI: 10.1002/ehf2.12222] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
375 Ha Y, Seo N, Shim JH, Kim SY, Park JA, Han S, Kim KW, Yu E, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study. J Gastroenterol Hepatol. 2015;30:1666-1672. [PMID: 25974139 DOI: 10.1111/jgh.12996] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
376 Corte CD, Iasevoli S, Strologo AD, Sanseviero M, Nobili V. Omega-3 Fatty Acids and Fatty Liver Disease in Children. Adv Food Nutr Res 2018;85:59-77. [PMID: 29860977 DOI: 10.1016/bs.afnr.2018.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
377 Hu M, Phan F, Bourron O, Ferré P, Foufelle F. Steatosis and NASH in type 2 diabetes. Biochimie 2017;143:37-41. [DOI: 10.1016/j.biochi.2017.10.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
378 Alkhouri N, Kheirandish-Gozal L, Matloob A, Alonso-Álvarez ML, Khalyfa A, Terán-Santos J, Okwu V, Lopez R, Gileles-Hillel A, Dweik R, Gozal D. Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apnea. Sleep Med 2015;16:1031-5. [PMID: 26298775 DOI: 10.1016/j.sleep.2015.05.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
379 Mandelia C, Collyer E, Mansoor S, Lopez R, Lappe S, Nobili V, Alkhouri N. Plasma Cytokeratin-18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2016;63:181-187. [PMID: 26835904 DOI: 10.1097/mpg.0000000000001136] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 7.3] [Reference Citation Analysis]
380 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016;7:211-7. [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
381 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 107] [Article Influence: 120.0] [Reference Citation Analysis]
382 Parry SA, Hodson L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J Investig Med 2017;65:1102-15. [PMID: 28947639 DOI: 10.1136/jim-2017-000524] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 13.8] [Reference Citation Analysis]
383 Valenti L, Dongiovanni P, Fargion S. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18:3782-3786. [PMID: 22876027 DOI: 10.3748/wjg.v18.i29.3782] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
384 Okamura K, Okuda T, Takamiya Y, Shirai K, Urata H. High Fib4 index in patients with suspected NASH is associated with elevation of chymase-dependent angiotensin II-forming activity in circulating mononuclear leucocytes. Heart Vessels 2019;34:1559-69. [PMID: 30919112 DOI: 10.1007/s00380-019-01391-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
385 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
386 Angulo P. Trial design in NASH—realities and challenges. Nat Rev Gastroenterol Hepatol 2011;8:424-5. [DOI: 10.1038/nrgastro.2011.125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
387 Zelber-Sagi S, Webb M, Assy N, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol 2013;19:57-64. [PMID: 23326163 DOI: 10.3748/wjg.v19.i1.57] [Cited by in CrossRef: 67] [Cited by in F6Publishing: 54] [Article Influence: 8.4] [Reference Citation Analysis]
388 Wong VW, Chan WK, Chitturi S, Chawla Y, Dan YY, Duseja A, Fan J, Goh KL, Hamaguchi M, Hashimoto E, Kim SU, Lesmana LA, Lin YC, Liu CJ, Ni YH, Sollano J, Wong SK, Wong GL, Chan HL, Farrell G. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33:70-85. [PMID: 28670712 DOI: 10.1111/jgh.13857] [Cited by in Crossref: 165] [Cited by in F6Publishing: 132] [Article Influence: 82.5] [Reference Citation Analysis]
389 Van Dijk AM, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, Anstee QM, Brosnan MJ, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:2910. [PMID: 34209858 DOI: 10.3390/jcm10132910] [Reference Citation Analysis]
390 Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT, Benjamin EJ, Levy D, Fox CS, Long MT. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66:390-397. [PMID: 27729222 DOI: 10.1016/j.jhep.2016.09.022] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 13.0] [Reference Citation Analysis]
391 Xin S, Zhan Q, Chen X, Xu J, Yu Y. Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:186. [PMID: 32532204 DOI: 10.1186/s12876-020-01334-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
392 Belemets N, Kobyliak N, Virchenko O, Falalyeyeva T, Olena T, Bodnar P, Savchuk O, Galenova T, Caprnda M, Rodrigo L, Skladany L, Delev D, Opatrilova R, Kruzliak P, Beregova T, Ostapchenko L. Effects of polyphenol compounds melanin on NAFLD/NASH prevention. Biomedicine & Pharmacotherapy 2017;88:267-76. [DOI: 10.1016/j.biopha.2017.01.028] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
393 Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Koyama M, Ohnishi H, Numata K, Hisasue T, Hanawa N, Moniwa N, Tsuchihashi K, Miura T. High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects. Sci Rep 2021;11:12830. [PMID: 34145341 DOI: 10.1038/s41598-021-92292-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
394 Karlas T, Petroff D, Garnov N, Böhm S, Tenckhoff H, Wittekind C, Wiese M, Schiefke I, Linder N, Schaudinn A. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One. 2014;9:e91987. [PMID: 24637477 DOI: 10.1371/journal.pone.0091987] [Cited by in Crossref: 80] [Cited by in F6Publishing: 70] [Article Influence: 11.4] [Reference Citation Analysis]
395 Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1724-1745. [PMID: 24587651 DOI: 10.3748/wjg.v20.i7.1724] [Cited by in CrossRef: 136] [Cited by in F6Publishing: 114] [Article Influence: 22.7] [Reference Citation Analysis]
396 Francque SM. The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. Eur Cardiol 2014;9:10-5. [PMID: 30310479 DOI: 10.15420/ecr.2014.9.1.10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
397 Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, McCullough A, Goodman Z, Younossi ZM. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017-3023. [PMID: 23775317 DOI: 10.1007/s10620-013-2743-5] [Cited by in Crossref: 152] [Cited by in F6Publishing: 137] [Article Influence: 19.0] [Reference Citation Analysis]
398 Corey KE, Chalasani N. Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:1077-84; quiz e59-60. [PMID: 23962548 DOI: 10.1016/j.cgh.2013.08.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
399 Stefano JT, Guedes LV, de Souza AAA, Vanni DS, Alves VAF, Carrilho FJ, Largura A, Arrese M, Oliveira CP. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Ann Hepatol 2021;20:100253. [PMID: 32949785 DOI: 10.1016/j.aohep.2020.08.070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
400 Szanto KB, Li J, Cordero P, Oben JA. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:357-367. [PMID: 30936733 DOI: 10.2147/dmso.s182331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
401 Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. Curr Pharm Des 2020;26:3928-38. [PMID: 32436818 DOI: 10.2174/1381612826666200521133307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
402 Liang J, Liu F, Wang F, Han T, Jing L, Ma Z, Gao Y. A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease. Biomed Res Int 2017;2017:8793278. [PMID: 28349067 DOI: 10.1155/2017/8793278] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
403 Spanos C, Maldonado EM, Fisher CP, Leenutaphong P, Oviedo-Orta E, Windridge D, Salguero FJ, Bermúdez-Fajardo A, Weeks ME, Evans C, Corfe BM, Rabbani N, Thornalley PJ, Miller MH, Wang H, Dillon JF, Quaglia A, Dhawan A, Fitzpatrick E, Moore JB. Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease. Proteome Sci 2018;16:4. [PMID: 29456458 DOI: 10.1186/s12953-018-0131-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
404 Buzzetti E, Lombardi R, De Luca L, Tsochatzis EA. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Int J Endocrinol 2015;2015:343828. [PMID: 26064107 DOI: 10.1155/2015/343828] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
405 Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F, Gambino R. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology. 2012;56:933-942. [PMID: 22684858 DOI: 10.1002/hep.25739] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 9.3] [Reference Citation Analysis]
406 Kamarajah SK, Chan WK, Nik Mustapha NR, Mahadeva S. Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease. Hepatol Int 2018;12:44-55. [PMID: 29372507 DOI: 10.1007/s12072-018-9843-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
407 Cui C, Deng J, Yan L, Liu Y, Fan J, Mu H, Sun H, Wang Y, Han J. Silibinin Capsules improves high fat diet-induced nonalcoholic fatty liver disease in hamsters through modifying hepatic de novo lipogenesis and fatty acid oxidation. Journal of Ethnopharmacology 2017;208:24-35. [DOI: 10.1016/j.jep.2017.06.030] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
408 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015;149:367-78.e5; quiz e14. [PMID: 25865049 DOI: 10.1053/j.gastro.2015.04.005] [Cited by in Crossref: 807] [Cited by in F6Publishing: 628] [Article Influence: 134.5] [Reference Citation Analysis]
409 Wijarnpreecha K, Kim D, Raymond P, Scribani M, Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur J Gastroenterol Hepatol 2019;31:1121-8. [PMID: 30888971 DOI: 10.1097/MEG.0000000000001397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
410 Önnerhag K, Hartman H, Nilsson PM, Lindgren S. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scandinavian Journal of Gastroenterology 2019;54:328-34. [DOI: 10.1080/00365521.2019.1583366] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
411 Khoo S, Wong VW, Goh GB, Fan J, Chan WK, Seto WK, Chow WC. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:320-5. [PMID: 31336392 DOI: 10.1111/jgh.14794] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
412 Shouhed D, Steggerda J, Burch M, Noureddin M. The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2017;11:797-811. [PMID: 28712339 DOI: 10.1080/17474124.2017.1355731] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
413 Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904. [DOI: 10.1007/s00125-011-2446-4] [Cited by in Crossref: 366] [Cited by in F6Publishing: 316] [Article Influence: 40.7] [Reference Citation Analysis]
414 Hassan K, Bhalla V, El Regal ME, A-Kader HH. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20:12082-12101. [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 79] [Article Influence: 17.3] [Reference Citation Analysis]
415 Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014;20:16820-30. [PMID: 25492996 DOI: 10.3748/wjg.v20.i45.16820] [Cited by in CrossRef: 89] [Cited by in F6Publishing: 61] [Article Influence: 14.8] [Reference Citation Analysis]
416 Chyau CC, Wang HF, Zhang WJ, Chen CC, Huang SH, Chang CC, Peng RY. Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway. Int J Mol Sci 2020;21:E360. [PMID: 31935815 DOI: 10.3390/ijms21010360] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
417 Arteaga I, Buezo I, Expósito C, Pera G, Rodríguez L, Alumà A, Auladell MA, Torán P, Caballería L. [Non-invasive markers of fibrosis in the diagnosis of non-alcoholic fatty liver disease]. Gastroenterol Hepatol 2014;37:503-10. [PMID: 24746708 DOI: 10.1016/j.gastrohep.2014.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
418 Xun YH, Fan JG, Zang GQ, Liu H, Jiang YM, Xiang J, Huang Q, Shi JP. Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease: Noninvasive tests for fibrosis in NAFLD. Journal of Digestive Diseases 2012;13:588-95. [DOI: 10.1111/j.1751-2980.2012.00631.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
419 Pulixi EA, Tobaldini E, Battezzati PM, D’Ingianna P, Borroni V, Fracanzani AL, Maggioni M, Pelusi S, Bulgheroni M, Zuin M. Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease. PLoS One. 2014;9:e96349. [PMID: 24763757 DOI: 10.1371/journal.pone.0096349] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
420 Li Q, Dhyani M, Grajo JR, Sirlin C, Samir AE. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018;10:530-542. [PMID: 30190781 DOI: 10.4254/wjh.v10.i8.530] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 25.0] [Reference Citation Analysis]
421 Belinchón-Romero I, Bellot P, Romero-Pérez D, Herraiz-Romero I, Marco F, Frances R, Ramos-Rincón JM. Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. Sci Rep 2021;11:8593. [PMID: 33883616 DOI: 10.1038/s41598-021-88043-8] [Reference Citation Analysis]
422 Susutlertpanya W, Wakuda H, Otani N, Kuramoto T, Li L, Kuranari M, Sekiguchi A, Kudo H, Uchida T, Imai H, Uemura N. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice. Life Sciences 2019;228:251-7. [DOI: 10.1016/j.lfs.2019.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
423 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
424 Yan LH, Mu B, Guan Y, Liu X, Zhao N, Pan D, Wang SZ. Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications. J Diabetes Investig 2016;7:889-94. [PMID: 27181828 DOI: 10.1111/jdi.12518] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
425 Simon TG, Corey KE, Chung RT, Giugliano R. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci 2016;61:3425-35. [DOI: 10.1007/s10620-016-4330-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
426 Eguchi A, Wree A, Feldstein AE. Biomarkers of liver cell death. J Hepatol. 2014;60:1063-1074. [PMID: 24412608 DOI: 10.1016/j.jhep.2013.12.026] [Cited by in Crossref: 109] [Cited by in F6Publishing: 95] [Article Influence: 15.6] [Reference Citation Analysis]
427 Almeda-valdes P, Aguilar-salinas CA, Uribe M, Canizales-quinteros S, Méndez-sánchez N. Impact of anthropometric cut-off values in determining the prevalence of metabolic alterations. Eur J Clin Invest 2016;46:940-6. [DOI: 10.1111/eci.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
428 Oikonomou D, Georgiopoulos G, Katsi V, Kourek C, Tsioufis C, Alexopoulou A, Koutli E, Tousoulis D. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur J Gastroenterol Hepatol. 2018;30:979-985. [PMID: 30048367 DOI: 10.1097/meg.0000000000001191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
429 Fujita T, Daimon M, Mizushiri S, Nishiya Y, Murakami H, Tanabe J, Matsuhashi Y, Yanagimachi M, Tokuda I, Sawada K, Ihara K. FIB-4 index is a marker for a subsequent decrease in insulin secretion in a non-diabetic Japanese population. Sci Rep 2020;10:15814. [PMID: 32978491 DOI: 10.1038/s41598-020-72894-8] [Reference Citation Analysis]
430 Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung S, Gu S, Rhee P, Paik SW, Son HJ, Gwak G. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther 2017;45:345-53. [DOI: 10.1111/apt.13866] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
431 Paschetta E, Belci P, Alisi A, Liccardo D, Cutrera R, Musso G, Nobili V. OSAS-related inflammatory mechanisms of liver injury in nonalcoholic fatty liver disease. Mediators Inflamm. 2015;2015:815721. [PMID: 25873773 DOI: 10.1155/2015/815721] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
432 Bo S, Gambino R, Menato G, Canil S, Ponzo V, Pinach S, Durazzo M, Ghigo E, Cassader M, Musso G. Isoleucine-to-methionine substitution at residue 148 variant of PNPLA3 gene and metabolic outcomes in gestational diabetes. Am J Clin Nutr 2015;101:310-8. [PMID: 25646328 DOI: 10.3945/ajcn.114.095125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
433 Semmler G, Wernly S, Bachmayer S, Leitner I, Wernly B, Egger M, Schwenoha L, Datz L, Balcar L, Semmler M, Stickel F, Niederseer D, Aigner E, Datz C. Metabolic dysfunction-associated fatty liver disease (MAFLD) - rather a bystander than a driver of mortality. J Clin Endocrinol Metab 2021:dgab339. [PMID: 33982065 DOI: 10.1210/clinem/dgab339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
434 Fitzpatrick E. Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum. Proc Nutr Soc 2019;78:362-71. [DOI: 10.1017/s0029665118002914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
435 Odena G, Chen J, Lozano JJ, Altamirano J, Rodrigo-Torres D, Affo S, Morales-Ibanez O, Matsushita H, Zou J, Dumitru R, Caballeria J, Gines P, Arroyo V, You M, Rautou PE, Valla D, Crews F, Seki E, Sancho-Bru P, Bataller R. LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. Sci Rep 2016;6:35610. [PMID: 27752144 DOI: 10.1038/srep35610] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
436 Mansour A, Mohajeri-Tehrani MR, Samadi M, Gerami H, Qorbani M, Bellissimo N, Poustchi H, Hekmatdoost A. Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients. Acta Diabetol 2019;56:1199-207. [PMID: 31197470 DOI: 10.1007/s00592-019-01374-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
437 Ma H, Cui F, Dong JJ, You GP, Yang XJ, Lu HD, Huang YL. Therapeutic effects of globular adiponectin in diabetic rats with nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:14950-14957. [PMID: 25356056 DOI: 10.3748/wjg.v20.i40.14950] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
438 Kobyliak N, Falalyeyeva T, Bodnar P, Beregova T. Probiotics Supplemented with Omega-3 Fatty Acids are More Effective for Hepatic Steatosis Reduction in an Animal Model of Obesity. Probiotics Antimicrob Proteins. 2017;9:123-130. [PMID: 27660157 DOI: 10.1007/s12602-016-9230-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
439 Bedossa P, Patel K, Castera L. Histologic and noninvasive estimates of liver fibrosis. Clin Liver Dis (Hoboken). 2015;6:5-8. [PMID: 31040975 DOI: 10.1002/cld.481] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
440 Tannapfel A, Dienes HP, Lohse AW. The indications for liver biopsy. Dtsch Arztebl Int. 2012;109:477-483. [PMID: 22833761 DOI: 10.3238/arztebl.2012.0477] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
441 Ahmed MH, Noor SK, Bushara SO, Husain NE, Elmadhoun WM, Ginawi IA, Osman MM, Mahmoud AO, Almobarak AO. Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System. Gastroenterology Res 2017;10:271-9. [PMID: 29118867 DOI: 10.14740/gr913w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
442 Liyanagedera S, Williams RP, Veraldi S, Nobili V, Mann JP. The pharmacological management of NAFLD in children and adolescents. Expert Rev Clin Pharmacol 2017;10:1225-37. [PMID: 28803504 DOI: 10.1080/17512433.2017.1365599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
443 Diehl DL, Johal AS, Khara HS, Stavropoulos SN, Al-Haddad M, Ramesh J, Varadarajulu S, Aslanian H, Gordon SR, Shieh FK, Pineda-Bonilla JJ, Dunkelberger T, Gondim DD, Chen EZ. Endoscopic ultrasound-guided liver biopsy: a multicenter experience. Endosc Int Open. 2015;3:E210-E215. [PMID: 26171433 DOI: 10.1055/s-0034-1391412] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
444 Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019;38:485-521. [PMID: 30712783 DOI: 10.1016/j.clnu.2018.12.022] [Cited by in F6Publishing: 88] [Reference Citation Analysis]
445 Zhan YT, Su HY, An W. Glycosyltransferases and non-alcoholic fatty liver disease. World J Gastroenterol 2016;22:2483-93. [PMID: 26937136 DOI: 10.3748/wjg.v22.i8.2483] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
446 Bajantri B, Lvovsky D. A Case of Concomitant Obstructive Sleep Apnea and Non-Alcoholic Steatohepatitis Treated With CPAP Therapy. Gastroenterology Res. 2018;11:252-259. [PMID: 29915639 DOI: 10.14740/gr1033w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
447 Chang Y, Jung H, Yun KE, Cho J, Cho YK, Ryu S. Cohort Study of Non-alcoholic Fatty Liver Disease, NAFLD fibrosis score, and the Risk of Incident Diabetes in a Korean population. American Journal of Gastroenterology 2013;108:1861-8. [DOI: 10.1038/ajg.2013.349] [Cited by in Crossref: 103] [Cited by in F6Publishing: 86] [Article Influence: 12.9] [Reference Citation Analysis]
448 Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637-653. [PMID: 25194181 DOI: 10.1016/j.bpg.2014.07.008] [Cited by in Crossref: 189] [Cited by in F6Publishing: 144] [Article Influence: 27.0] [Reference Citation Analysis]
449 Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res. 2011;42:337-353. [PMID: 21843565 DOI: 10.1016/j.arcmed.2011.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
450 Murayama K, Okada M, Tanaka K, Inadomi C, Yoshioka W, Kubotsu Y, Yada T, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Oza N, Hyogo H, Ono M, Kawaguchi T, Torimura T, Anzai K, Eguchi Y, Takahashi H. Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. Diagnostics (Basel) 2021;11:132. [PMID: 33467114 DOI: 10.3390/diagnostics11010132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
451 Jaruvongvanich V, Wijarnpreecha K, Ungprasert P. The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study. Clinics and Research in Hepatology and Gastroenterology 2017;41:629-34. [DOI: 10.1016/j.clinre.2017.03.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
452 Goh GB, McCullough AJ. Natural History of Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2016;61:1226-33. [PMID: 27003142 DOI: 10.1007/s10620-016-4095-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 13.4] [Reference Citation Analysis]
453 Singh A, Le P, Peerzada MM, Lopez R, Alkhouri N. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients. Journal of Clinical Gastroenterology 2018;52:268-72. [DOI: 10.1097/mcg.0000000000000905] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 4.7] [Reference Citation Analysis]
454 Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015;47:997-1006. [PMID: 26454786 DOI: 10.1016/j.dld.2015.08.004] [Cited by in Crossref: 246] [Cited by in F6Publishing: 202] [Article Influence: 41.0] [Reference Citation Analysis]
455 Le MH, Devaki P, Ha NB, Jun DW, Te HS, Cheung RC, Nguyen MH. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One. 2017;12:e0173499. [PMID: 28346543 DOI: 10.1371/journal.pone.0173499] [Cited by in Crossref: 116] [Cited by in F6Publishing: 98] [Article Influence: 29.0] [Reference Citation Analysis]
456 García Díaz E, Guagnozzi D, Gutiérrez V, Mendoza C, Maza C, Larrañaga Y, Perdomo D, Godoy T, Taleb G. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. Endocrinol Nutr 2016;63:194-201. [PMID: 26976710 DOI: 10.1016/j.endonu.2016.01.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
457 Armstrong MJ, Hazlehurst JM, Parker R, Koushiappi E, Mann J, Khan S, Philips A, Chandler L, Johnson J, Round M, Haydon G, Karamat MA, Newsome PN, Tomlinson JW. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM 2014;107:33-41. [PMID: 24131545 DOI: 10.1093/qjmed/hct198] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
458 Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2020;. [PMID: 32938692 DOI: 10.1136/gutjnl-2020-322572] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 29.0] [Reference Citation Analysis]
459 Alswat KA, Fallatah HI, Al-Judaibi B, Elsiesy HA, Al-Hamoudi WK, Qutub AN, Alturaify N, Al-Osaimi A. Position statement on the diagnosis and management of non-alcoholic fatty liver disease. Saudi Med J 2019;40:531-40. [PMID: 31219486 DOI: 10.15537/smj.2019.6.23980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
460 Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40:1367-1393. [PMID: 31098621 DOI: 10.1210/er.2019-00034] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 66.0] [Reference Citation Analysis]
461 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017;6:62-72. [PMID: 31646122 DOI: 10.1097/XCE.0000000000000126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
462 Kumar R, Porwal YC, Dev N, Kumar P, Chakravarthy S, Kumawat A. Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. J Family Med Prim Care 2020;9:390-4. [PMID: 32110624 DOI: 10.4103/jfmpc.jfmpc_887_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
463 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 12.8] [Reference Citation Analysis]
464 Zhao Y, Zhang L, Ouyang X, Jiang Z, Xie Z, Fan L, Zhu D, Li L. Advanced oxidation protein products play critical roles in liver diseases. Eur J Clin Invest 2019;:e13098. [PMID: 30838641 DOI: 10.1111/eci.13098] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
465 Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ 2014;349:g4596. [PMID: 25239614 DOI: 10.1136/bmj.g4596] [Cited by in Crossref: 157] [Cited by in F6Publishing: 129] [Article Influence: 22.4] [Reference Citation Analysis]
466 Jeong SW. Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. Diabetes Metab J. 2020;44:640-657. [PMID: 33115209 DOI: 10.4093/dmj.2020.0115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
467 Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci 2016;61:2108-17. [PMID: 26825843 DOI: 10.1007/s10620-016-4044-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
468 Rosso N, Stephenson AM, Giraudi PJ, Tiribelli C. Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools-a narrative review. Ann Transl Med 2021;9:727. [PMID: 33987425 DOI: 10.21037/atm-20-4723] [Reference Citation Analysis]
469 Kosick HM, Keyrouz A, Adeyi O, Sebastiani G, Patel K. A Stepwise Algorithmic Approach and External Validation Study for Noninvasive Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2021. [PMID: 33389416 DOI: 10.1007/s10620-020-06748-8] [Reference Citation Analysis]
470 Gerges SH, Wahdan SA, Elsherbiny DA, El-Demerdash E. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. Life Sci 2021;271:119220. [PMID: 33592199 DOI: 10.1016/j.lfs.2021.119220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
471 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
472 Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol. 2014;20:14185-14204. [PMID: 25339806 DOI: 10.3748/wjg.v20.i39.14185] [Cited by in CrossRef: 137] [Cited by in F6Publishing: 106] [Article Influence: 22.8] [Reference Citation Analysis]
473 Patterson RE, Kalavalapalli S, Williams CM, Nautiyal M, Mathew JT, Martinez J, Reinhard MK, McDougall DJ, Rocca JR, Yost RA, Cusi K, Garrett TJ, Sunny NE. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. Am J Physiol Endocrinol Metab. 2016;310:E484-E494. [PMID: 26814015 DOI: 10.1152/ajpendo.00492.2015] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 13.8] [Reference Citation Analysis]
474 Radmard AR, Poustchi H, Dadgostar M, Yoonessi A, Kooraki S, Jafari E, Hashemi Taheri AP, Malekzadeh R, Merat S. Liver enzyme levels and hepatic iron content in Fatty liver: a noninvasive assessment in general population by T2* mapping. Acad Radiol. 2015;22:714-721. [PMID: 25754799 DOI: 10.1016/j.acra.2015.01.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
475 Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, Kim CW, Jo SH, Lee CD, Lee YS, Choi SW, Yang JM, Jang JW, Kim SG, Jung SW, Kim HK, Chae HB, Yoon SK. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:120-30. [PMID: 23837136 DOI: 10.3350/cmh.2013.19.2.120] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
476 Boland BS, Edelman SV, Wolosin JD. Gastrointestinal complications of diabetes. Endocrinol Metab Clin North Am 2013;42:809-32. [PMID: 24286951 DOI: 10.1016/j.ecl.2013.07.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
477 Anstee QM, Seth D, Day CP. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1728-1744.e7. [PMID: 26873399 DOI: 10.1053/j.gastro.2016.01.037] [Cited by in Crossref: 121] [Cited by in F6Publishing: 102] [Article Influence: 24.2] [Reference Citation Analysis]
478 Bozic MA, Subbarao G, Molleston JP. Pediatric Nonalcoholic Fatty Liver Disease. Nutr Clin Pract 2013;28:448-58. [DOI: 10.1177/0884533613489153] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
479 Alam S, Jahid Hasan M, Khan MAS, Alam M, Hasan N. Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient. J Transl Int Med 2019;7:106-14. [PMID: 31637181 DOI: 10.2478/jtim-2019-0023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
480 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
481 Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357-1365. [PMID: 23175136 DOI: 10.1002/hep.26156] [Cited by in Crossref: 410] [Cited by in F6Publishing: 350] [Article Influence: 51.3] [Reference Citation Analysis]
482 Tilg H, Diehl AM. NAFLD and extrahepatic cancers: have a look at the colon. Gut 2011;60:745-6. [PMID: 21454382 DOI: 10.1136/gut.2011.239392] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
483 Lee CO, Li HL, Tsoi MF, Cheung CL, Cheung BMY. Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999-2016. Ann Med 2021;53:1065-73. [PMID: 34184611 DOI: 10.1080/07853890.2021.1943514] [Reference Citation Analysis]
484 Martini A, Fattovich G, Guido M, Bugianesi E, Biasiolo A, Ieluzzi D, Gallotta A, Fassina G, Merkel C, Gatta A, Negro F, Pontisso P. HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. J Viral Hepat 2015;22:800-8. [DOI: 10.1111/jvh.12394] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
485 Dallio M, Diano N, Masarone M, Gravina AG, Patanè V, Romeo M, Di Sarno R, Errico S, Nicolucci C, Abenavoli L, Scarpellini E, Boccuto L, Persico M, Loguercio C, Federico A. Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. Int J Environ Res Public Health 2019;16:E3134. [PMID: 31466361 DOI: 10.3390/ijerph16173134] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
486 Acharya UR, Faust O, Molinari F, Sree SV, Junnarkar SP, Sudarshan V. Ultrasound-based tissue characterization and classification of fatty liver disease: A screening and diagnostic paradigm. Knowledge-Based Systems 2015;75:66-77. [DOI: 10.1016/j.knosys.2014.11.021] [Cited by in Crossref: 54] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
487 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596. [PMID: 22526604 DOI: 10.1007/s00125-012-2534-0] [Cited by in Crossref: 968] [Cited by in F6Publishing: 719] [Article Influence: 107.6] [Reference Citation Analysis]
488 Sharma V, Juglan K. Automated Classification of Fatty and Normal Liver Ultrasound Images Based on Mutual Information Feature Selection. IRBM 2018;39:313-23. [DOI: 10.1016/j.irbm.2018.09.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
489 Seen TK, Sayed M, Bilal M, Reyes JV, Bhandari P, Lourdusamy V, Al-Khazraji A, Syed U, Sattar Y, Bansal R. Clinical indicators for progression of nonalcoholic steatohepatitis to cirrhosis. World J Gastroenterol 2021;27:3238-48. [PMID: 34163108 DOI: 10.3748/wjg.v27.i23.3238] [Reference Citation Analysis]
490 Boursier J, Vergniol J, Guillet A, Hiriart J, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-hubert I, Rousselet M, Calès P, de Lédinghen V. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. Journal of Hepatology 2016;65:570-8. [DOI: 10.1016/j.jhep.2016.04.023] [Cited by in Crossref: 183] [Cited by in F6Publishing: 141] [Article Influence: 36.6] [Reference Citation Analysis]
491 Ofosu A, Ramai D, Reddy M. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. Ann Gastroenterol. 2018;31:288-295. [PMID: 29720854 DOI: 10.20524/aog.2018.0240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
492 Sinn DH, Kang D, Jang HR, Gu S, Cho SJ, Paik SW, Ryu S, Chang Y, Lazo M, Guallar E, Cho J, Gwak GY. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: A cohort study. J Hepatol. 2017;67:1274-1280. [PMID: 28870674 DOI: 10.1016/j.jhep.2017.08.024] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 16.5] [Reference Citation Analysis]
493 Festi D, Schiumerini R, Marasco G, Scaioli E, Pasqui F, Colecchia A. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology & Hepatology 2015;9:1039-53. [DOI: 10.1586/17474124.2015.1049155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
494 Yoneda M, Imajo K, Takahashi H, Ogawa Y, Eguchi Y, Sumida Y, Yoneda M, Kawanaka M, Saito S, Tokushige K, Nakajima A. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol 2018;53:181-96. [PMID: 29177681 DOI: 10.1007/s00535-017-1414-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
495 Hashimoto E, Taniai M, Tokushige K. Characteristics and diagnosis of NAFLD/NASH. J Gastroenterol Hepatol. 2013;28 Suppl 4:64-70. [PMID: 24251707 DOI: 10.1111/jgh.12271] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 16.7] [Reference Citation Analysis]
496 Yu AH, Duan-Mu YY, Zhang Y, Wang L, Guo Z, Yu YQ, Wang YS, Cheng XG. Correlation between Non-Alcoholic Fatty Liver Disease and Visceral Adipose Tissue in Non-Obese Chinese Adults: A CT Evaluation. Korean J Radiol. 2018;19:923-929. [PMID: 30174482 DOI: 10.3348/kjr.2018.19.5.923] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
497 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2013;19:325-48. [PMID: 24459637 DOI: 10.3350/cmh.2013.19.4.325] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 9.4] [Reference Citation Analysis]
498 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379. [PMID: 22517736 DOI: 10.2337/dc12-0413] [Cited by in Crossref: 2335] [Cited by in F6Publishing: 1743] [Article Influence: 259.4] [Reference Citation Analysis]
499 Reisberg S, Galwey N, Avillach P, Sahlqvist AS, Kolberg L, Mägi R, Esko T, Vilo J, James G. Comparison of variation in frequency for SNPs associated with asthma or liver disease between Estonia, HapMap populations and the 1000 genome project populations. Int J Immunogenet 2019;46:49-58. [PMID: 30659741 DOI: 10.1111/iji.12413] [Reference Citation Analysis]
500 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 131] [Article Influence: 19.9] [Reference Citation Analysis]
501 Singh SP, Barik RK. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? J Clin Exp Hepatol 2020;10:88-98. [PMID: 32025168 DOI: 10.1016/j.jceh.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
502 Mohammadi F, Qorbani M, Kelishadi R, Baygi F, Ardalan G, Taslimi M, Mahmoudarabi M, Motlagh M, Asayesh H, Larijani B, Heshmat R. Association of Cardiometabolic Risk Factors and Hepatic Enzymes in a National Sample of Iranian Children and Adolescents: The CASPIAN-III Study. Journal of Pediatric Gastroenterology & Nutrition 2014;58:463-8. [DOI: 10.1097/mpg.0000000000000246] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
503 Hempel F, Roderfeld M, Müntnich LJ, Albrecht J, Oruc Z, Arneth B, Karrasch T, Pons-Kühnemann J, Padberg W, Renz H, Schäffler A, Roeb E. Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. J Clin Med 2021;10:1233. [PMID: 33809676 DOI: 10.3390/jcm10061233] [Reference Citation Analysis]
504 Choi W, Lee J, Yoon J, Kwak C, Lee YJ, Cho YY, Lee YB, Yu SJ, Kim YJ, Kim HH, Kim H, Cho SY, Lee SB, Jeong H, Kim CY, Lee H. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocrine-Related Cancer 2014;21:343-53. [DOI: 10.1530/erc-14-0036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
505 Kimura T, Deshpande GA, Urayama KY, Masuda K, Fukui T, Matsuyama Y. Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals. J Gastroenterol Hepatol 2015;30:909-17. [PMID: 25469977 DOI: 10.1111/jgh.12861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
506 El-Aziz RA, Alnaggar ARLR, Mohamed Nabih MI, Ali SM, Khattab H, El-Atty SA. Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study. Clin Exp Hepatol 2020;6:28-34. [PMID: 32166121 DOI: 10.5114/ceh.2020.93053] [Reference Citation Analysis]
507 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 91] [Article Influence: 9.8] [Reference Citation Analysis]
508 Xanthakos SA. Noninvasive Assessment of Nonalcoholic Steatohepatitis and Nonalcoholic Steatohepatitis-Related Fibrosis: Is There a Role for Cytokeratin 18? Journal of Pediatric Gastroenterology & Nutrition 2016;63:167-8. [DOI: 10.1097/mpg.0000000000001193] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
509 Zhao H, Yang A, Mao L, Quan Y, Cui J, Sun Y. Association Between Dietary Fiber Intake and Non-alcoholic Fatty Liver Disease in Adults. Front Nutr 2020;7:593735. [PMID: 33330594 DOI: 10.3389/fnut.2020.593735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
510 Nakamura A, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Okanoue T, Nakajima A, Maeda S, Terauchi Y. Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease. J Diabetes Investig. 2013;4:651-658. [PMID: 24843721 DOI: 10.1111/jdi.12101] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
511 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
512 Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21:7427-7435. [PMID: 26139988 DOI: 10.3748/wjg.v21.i24.7427] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
513 Junker AE, Gluud LL, Pedersen J, Langhoff JL, Holst JJ, Knop FK, Vilsbøll T. A 25-year-old woman with type 2 diabetes and liver disease. Case Rep Gastroenterol 2014;8:398-403. [PMID: 25606030 DOI: 10.1159/000369968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
514 Lomonaco R, Chen J, Cusi K. An endocrine perspective of nonalcoholic fatty liver disease (NAFLD). Ther Adv Endocrinol Metab. 2011;2:211-225. [PMID: 23148186 DOI: 10.1177/2042018811419157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
515 Kobyliak N, Falalyeyeva T, Virchenko O, Mykhalchyshyn G, Bodnar P, Spivak M, Yankovsky D, Beregova T, Ostapchenko L. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention. BMC Gastroenterol. 2016;16:34. [PMID: 26976285 DOI: 10.1186/s12876-016-0451-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
516 Fujiwara Y, Kuroda H, Abe T, Ishida K, Oguri T, Noguchi S, Sugai T, Kamiyama N, Takikawa Y. The B-Mode Image-Guided Ultrasound Attenuation Parameter Accurately Detects Hepatic Steatosis in Chronic Liver Disease. Ultrasound Med Biol. 2018;44:2223-2232. [PMID: 30077415 DOI: 10.1016/j.ultrasmedbio.2018.06.017] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 11.3] [Reference Citation Analysis]
517 Koplay M, Sivri M, Erdogan H, Nayman A. Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015;7:769-776. [PMID: 25914777 DOI: 10.4254/wjh.v7.i5.769] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
518 Mazzolini G, Sowa J, Canbay A. Cell death mechanisms in human chronic liver diseases: a far cry from clinical applicability. Clinical Science 2016;130:2121-38. [DOI: 10.1042/cs20160035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
519 Lonardo A, Ballestri S, Targher G, Loria P. Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2015;9:629-50. [DOI: 10.1586/17474124.2015.965143] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
520 Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019;34:449-57. [DOI: 10.1093/ndt/gfx381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
521 Mykhalchyshyn G, Kobyliak N, Bodnar P. Diagnostic accuracy of acyl-ghrelin and it association with non-alcoholic fatty liver disease in type 2 diabetic patients. J Diabetes Metab Disord. 2015;14:44. [PMID: 25995986 DOI: 10.1186/s40200-015-0170-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
522 Popov VB, Lim JK. Treatment of Nonalcoholic Fatty Liver Disease: The Role of Medical, Surgical, and Endoscopic Weight Loss. J Clin Transl Hepatol. 2015;3:230-238. [PMID: 26623270 DOI: 10.14218/jcth.2015.00019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 4.2] [Reference Citation Analysis]
523 Sakpal M, Satsangi S, Mehta M, Duseja A, Bhadada S, Das A, Dhiman RK, Chawla YK. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial. JGH Open. 2017;1:62-67. [PMID: 30483536 DOI: 10.1002/jgh3.12010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
524 Winn NC, Liu Y, Rector RS, Parks EJ, Ibdah JA, Kanaley JA. Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity — A randomized trial. Metabolism 2018;78:128-40. [DOI: 10.1016/j.metabol.2017.08.012] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 15.3] [Reference Citation Analysis]
525 Ye Z, Wang S, Yang Z, He M, Zhang S, Zhang W, Wen J, Li Q, Huang Y, Wang X, Lu B, Zhang Z, Su Q, Hu R. Serum lipocalin-2, cathepsin S and chemerin levels and nonalcoholic fatty liver disease. Mol Biol Rep 2014;41:1317-23. [PMID: 24390241 DOI: 10.1007/s11033-013-2977-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
526 Kuchay MS, Choudhary NS, Mishra SK, Misra A. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes. Diabetes Metab Syndr 2020;14:2233-9. [PMID: 33336648 DOI: 10.1016/j.dsx.2020.11.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
527 Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, Clark L, Hooker J, Chavez T, Ang BD, Middleton MS, Peterson M, Loomba R, Sirlin CB. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 2015;274:416-25. [PMID: 25247408 DOI: 10.1148/radiol.14140754] [Cited by in Crossref: 131] [Cited by in F6Publishing: 101] [Article Influence: 18.7] [Reference Citation Analysis]
528 Musso G, Cassader M, Olivetti C, Rosina F, Carbone G, Gambino R. Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. Obes Rev. 2013;14:417-431. [PMID: 23387384 DOI: 10.1111/obr.12020] [Cited by in Crossref: 131] [Cited by in F6Publishing: 111] [Article Influence: 16.4] [Reference Citation Analysis]
529 Polyzos SA, Mantzoros CS. Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease. Metabolism 2014;63:161-7. [DOI: 10.1016/j.metabol.2013.10.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 6.1] [Reference Citation Analysis]
530 Farzin L, Asghari S, Rafraf M, Asghari-Jafarabadi M, Shirmohammadi M. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. Int J Vitam Nutr Res 2020;90:279-89. [PMID: 30789808 DOI: 10.1024/0300-9831/a000528] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
531 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 51] [Article Influence: 16.8] [Reference Citation Analysis]
532 Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Main Text. Curr Vasc Pharmacol 2019;17:498-514. [PMID: 31060488 DOI: 10.2174/1570161117666190507110519] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 19.0] [Reference Citation Analysis]
533 Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711-725.e6. [PMID: 22326434 DOI: 10.1053/j.gastro.2012.02.003] [Cited by in Crossref: 482] [Cited by in F6Publishing: 417] [Article Influence: 53.6] [Reference Citation Analysis]
534 Watanabe K, Ohta M, Takayama H, Tada K, Shitomi Y, Kawasaki T, Kawano Y, Endo Y, Iwashita Y, Inomata M. Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model. OBES SURG 2018;28:1532-9. [DOI: 10.1007/s11695-017-3052-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
535 El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E2215. [PMID: 31064058 DOI: 10.3390/ijms20092215] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
536 Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dhawan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatr Obes. 2012;7:471-479. [PMID: 22962039 DOI: 10.1111/j.2047-6310.2012.00082.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
537 Macaluso FS, Maida M, Petta S. Genetic background in nonalcoholic fatty liver disease: A comprehensive review. World J Gastroenterol 2015;21:11088-111. [PMID: 26494964 DOI: 10.3748/wjg.v21.i39.11088] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
538 Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1-9. [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
539 Xin YN, Geng N, Lin ZH, Cui YZ, Duan HP, Zhang M, Xuan SY. Serum complement C3f and fibrinopeptide A are potential novel diagnostic biomarkers for non-alcoholic fatty liver disease: a study in Qingdao Twins. PLoS One 2014;9:e108132. [PMID: 25250770 DOI: 10.1371/journal.pone.0108132] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
540 Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315. [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013] [Cited by in Crossref: 190] [Cited by in F6Publishing: 151] [Article Influence: 47.5] [Reference Citation Analysis]
541 Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, Pastor-Barriuso R, Ahn J, Kim CW, Rampal S. Metabolically Healthy Obesity and the Development of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2016;111:1133-1140. [PMID: 27185080 DOI: 10.1038/ajg.2016.178] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 18.2] [Reference Citation Analysis]
542 Zhang H, Shen WJ, Li Y, Bittner A, Bittner S, Tabassum J, Cortez YF, Kraemer FB, Azhar S. Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats. Nutr Metab (Lond) 2016;13:63. [PMID: 27708683 DOI: 10.1186/s12986-016-0121-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
543 Friedrich-Rust M, Schoelzel F, Maier S, Seeger F, Rey J, Fichtlscherer S, Herrmann E, Zeuzem S, Bojunga J. Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study. PLoS One 2017;12:e0186720. [PMID: 29073252 DOI: 10.1371/journal.pone.0186720] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
544 Kage M, Aishima S, Kusano H, Yano H. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Med Ultrason (2001) 2020;47:549-54. [PMID: 33136250 DOI: 10.1007/s10396-020-01061-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
545 Tomasiewicz K, Flisiak R, Halota W, Jaroszewicz J, Lebensztejn D, Lisik W, Małkowski P, Pawłowska M, Piekarska A, Simon K, Tronina O; Recommendations of the Polish Group of Experts for Non-Alcoholic Fatty Liver Disease (PGE-NAFLD). Recommendations for the management of non-alcoholic fatty liver disease (NAFLD). Clin Exp Hepatol 2018;4:153-7. [PMID: 30324139 DOI: 10.5114/ceh.2018.78118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
546 Camarena C, Aldamiz-Echevarria LJ, Polo B, Barba Romero MA, García I, Cebolla JJ, Ros E. Update on lysosomal acid lipase deficiency: Diagnosis, treatment and patient management. Med Clin (Barc) 2017;148:429.e1-429.e10. [PMID: 28285817 DOI: 10.1016/j.medcli.2016.12.044] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
547 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264-1281.e4. [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036] [Cited by in Crossref: 310] [Cited by in F6Publishing: 248] [Article Influence: 155.0] [Reference Citation Analysis]
548 Losekann A, Weston AC, Carli LA, Espindola MB, Pioner SR, Coral GP. Nonalcoholic fatty liver disease in severe obese patients, subjected to bariatric surgery. Arq Gastroenterol. 2013;50:285-289. [PMID: 24474231 DOI: 10.1590/s0004-28032013000400009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
549 Tariq R, Axley P, Singal AK. Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review. J Clin Exp Hepatol 2020;10:81-7. [PMID: 32025167 DOI: 10.1016/j.jceh.2019.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
550 Hama M, Horie R, Kubota T, Matsumura T, Kimura E, Nakamura H, Takahashi MP, Takada H. Metabolic complications in myotonic dystrophy type 1: A cross-sectional survey using the National Registry of Japan. J Neurol Sci 2021;427:117511. [PMID: 34082146 DOI: 10.1016/j.jns.2021.117511] [Reference Citation Analysis]
551 Liebig S, Stoeckmann N, Geier A, Rau M, Schattenberg JM, Bahr MJ, Manns MP, Jaeckel E, Schulze-Osthoff K, Bantel H. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness. Clin Transl Gastroenterol 2019;10:e00066. [PMID: 31397685 DOI: 10.14309/ctg.0000000000000066] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
552 Povsic M, Wong OY, Perry R, Bottomley J. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH). Adv Ther 2019;36:1574-94. [PMID: 31065991 DOI: 10.1007/s12325-019-00960-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 13.0] [Reference Citation Analysis]
553 Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012;91:319-327. [PMID: 23117851 DOI: 10.1097/md.0b013e3182779d49] [Cited by in Crossref: 280] [Cited by in F6Publishing: 131] [Article Influence: 35.0] [Reference Citation Analysis]
554 Leite NC, Villela-Nogueira CA, Cardoso CR, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol. 2014;20:8377-8392. [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
555 Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliðadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014;11:e1001680. [PMID: 25050550 DOI: 10.1371/journal.pmed.1001680] [Cited by in Crossref: 283] [Cited by in F6Publishing: 239] [Article Influence: 40.4] [Reference Citation Analysis]
556 Nobili V, Svegliati-baroni G, Alisi A, Miele L, Valenti L, Vajro P. A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology 2013;58:1218-29. [DOI: 10.1016/j.jhep.2012.12.003] [Cited by in Crossref: 106] [Cited by in F6Publishing: 89] [Article Influence: 13.3] [Reference Citation Analysis]
557 Musso G, De Michieli F, Bongiovanni D, Parente R, Framarin L, Leone N, Berrutti M, Gambino R, Cassader M, Cohney S, Paschetta E. New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease. Clin Gastroenterol Hepatol 2017;15:972-85. [PMID: 27521506 DOI: 10.1016/j.cgh.2016.08.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
558 Issa D, Patel V, Sanyal AJ. Future therapy for non-alcoholic fatty liver disease. Liver Int 2018;38 Suppl 1:56-63. [PMID: 29427492 DOI: 10.1111/liv.13676] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
559 Giannetti M, Piaggi P, Ceccarini G, Mazzeo S, Querci G, Fierabracci P, Salvetti G, Galli G, Ricco I, Martinelli S, Di Salvo C, Anselmino M, Landi A, Vitti P, Pinchera A, Santini F. Hepatic left lobe volume is a sensitive index of metabolic improvement in obese women after gastric banding. Int J Obes (Lond). 2012;36:336-341. [PMID: 22143620 DOI: 10.1038/ijo.2011.243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
560 Yoshimura K, Okanoue T, Ebise H, Iwasaki T, Mizuno M, Shima T, Ichihara J, Yamazaki K. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology 2016;63:462-73. [PMID: 26390046 DOI: 10.1002/hep.28226] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
561 Sheldon RD, Laughlin MH, Rector RS. Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats. J Appl Physiol (1985) 2014;116:1156-64. [PMID: 24577062 DOI: 10.1152/japplphysiol.01275.2013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
562 Hernandez-Alejandro R, Croome KP, Drage M, Sela N, Parfitt J, Chandok N, Marotta P, Dale C, Wall W, Quan D. A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma. World J Gastroenterol. 2012;18:4145-4149. [PMID: 22919246 DOI: 10.3748/wjg.v18.i31.4145] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
563 Kim D, Kim WR. Nonobese Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017;15:474-485. [PMID: 27581063 DOI: 10.1016/j.cgh.2016.08.028] [Cited by in Crossref: 149] [Cited by in F6Publishing: 125] [Article Influence: 29.8] [Reference Citation Analysis]
564 Mandelia C, Kabbany MN, Conjeevaram Selvakumar PK, Alkhouri N. The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease. Biomark Med 2018;12:265-73. [PMID: 29517271 DOI: 10.2217/bmm-2017-0038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
565 Musso G. Ezetimibe in the balance: can cholesterol-lowering drugs alone be an effective therapy for NAFLD? Diabetologia. 2014;57:850-855. [PMID: 24554006 DOI: 10.1007/s00125-014-3192-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
566 Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896-904. [PMID: 29886156 DOI: 10.1016/j.jhep.2018.05.036] [Cited by in Crossref: 381] [Cited by in F6Publishing: 308] [Article Influence: 127.0] [Reference Citation Analysis]
567 Altaf B, Rehman A, Jawed S, Raouf A. Association of liver biomarkers and cytokeratin-18 in Nonalcoholic fatty liver disease patients. Pak J Med Sci 2020;36:387-90. [PMID: 32292439 DOI: 10.12669/pjms.36.3.1674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
568 Keramida G, Hunter J, Dizdarevic S, Peters AM. Heterogeneity of intrahepatic fat distribution determined by 18F-FDG PET and CT. Ann Nucl Med 2016;30:200-6. [DOI: 10.1007/s12149-015-1045-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
569 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver. Exp Ther Med 2014;8:759-62. [PMID: 25120595 DOI: 10.3892/etm.2014.1798] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
570 Patel K, Shackel NA. Current status of fibrosis markers. Curr Opin Gastroenterol. 2014;30:253-259. [PMID: 24671009 DOI: 10.1097/mog.0000000000000059] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
571 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
572 Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015;16:541-57. [PMID: 26406351 DOI: 10.1111/1751-2980.12291] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 11.6] [Reference Citation Analysis]
573 Feldstein AE, Alkhouri N, De Vito R, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol. 2013;108:1526-1531. [PMID: 23752877 DOI: 10.1038/ajg.2013.168] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 10.1] [Reference Citation Analysis]
574 White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342-1359.e2. [PMID: 23041539 DOI: 10.1016/j.cgh.2012.10.001] [Cited by in Crossref: 413] [Cited by in F6Publishing: 365] [Article Influence: 45.9] [Reference Citation Analysis]
575 Nampoothiri RV, Duseja A, Rathi M, Agrawal S, Sachdeva N, Mehta M, Dhaliwal HS, Dhiman RK, Chawla Y. Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. J Clin Exp Hepatol. 2019;9:22-28. [PMID: 30765935 DOI: 10.1016/j.jceh.2017.12.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
576 Singh A, Kumar MS, Jaryal AK, Ranjan P, Deepak KK, Sharma S, Lakshmy R, Pandey RM, Vikram NK. Diabetic status and grade of nonalcoholic fatty liver disease are associated with lower baroreceptor sensitivity in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2017;29:956-61. [PMID: 28471821 DOI: 10.1097/MEG.0000000000000898] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
577 van Enst WA, Scholten RJ, Whiting P, Zwinderman AH, Hooft L. Meta-epidemiologic analysis indicates that MEDLINE searches are sufficient for diagnostic test accuracy systematic reviews. J Clin Epidemiol 2014;67:1192-9. [PMID: 24996667 DOI: 10.1016/j.jclinepi.2014.05.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
578 Lykiardopoulos B, Hagström H, Fredrikson M, Ignatova S, Stål P, Hultcrantz R, Ekstedt M, Kechagias S. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS One 2016;11:e0167776. [PMID: 27936091 DOI: 10.1371/journal.pone.0167776] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
579 Tula E, Ergun T, Seckin D, Ozgen Z, Avsar E. Psoriasis and the liver: problems, causes and course. Australas J Dermatol 2017;58:194-9. [PMID: 26916498 DOI: 10.1111/ajd.12460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
580 Schreiner AD, Zhang J, Durkalski-Mauldin V, Livingston S, Marsden J, Bian J, Mauldin PD, Moran WP, Rockey DC. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev 2021. [PMID: 33759300 DOI: 10.1002/dmrr.3452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
581 Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol. 2012;27:420-428. [PMID: 22596186 DOI: 10.1097/hco.0b013e328354829c] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
582 Jin R, Le NA, Liu S, Farkas Epperson M, Ziegler TR, Welsh JA, Jones DP, McClain CJ, Vos MB. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab 2012;97:E1088-98. [PMID: 22544914 DOI: 10.1210/jc.2012-1370] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
583 Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
584 Jung TW, Park HS, Choi GH, Kim D, Jeong JH, Lee T. Chitinase‐3‐like protein 1 ameliorates atherosclerotic responses via PPARδ‐mediated suppression of inflammation and ER stress. J Cell Biochem 2018;119:6795-805. [DOI: 10.1002/jcb.26873] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
585 Vander Naalt SJ, Gurria JP, Holterman AL. Surgical treatment of nonalcoholic fatty liver disease in severely obese patients. Hepat Med 2014;6:103-12. [PMID: 25378958 DOI: 10.2147/HMER.S64819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
586 Noureddin M, Loomba R. Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. Clin Liver Dis (Hoboken) 2012;1:104-7. [PMID: 31186861 DOI: 10.1002/cld.65] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
587 Singh A, Le P, Lopez R, Alkhouri N. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients. Hepatol Int 2018;12:37-43. [PMID: 29318450 DOI: 10.1007/s12072-017-9840-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
588 Meneses D, Olveira A, Corripio R, del Carmen Méndez M, Romero M, Calvo-viñuelas I, Herranz L, Vicent D, de-Cos-Blanco AI. Performance of Noninvasive Liver Fibrosis Scores in the Morbid Obese Patient, Same Scores but Different Thresholds. OBES SURG 2020;30:2538-46. [DOI: 10.1007/s11695-020-04509-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
589 Arısoy A, Sertoğullarından B, Ekin S, Özgökçe M, Bulut MD, Huyut MT, Ölmez Ş, Turan M. Sleep Apnea and Fatty Liver Are Coupled Via Energy Metabolism. Med Sci Monit 2016;22:908-13. [PMID: 26993969 DOI: 10.12659/msm.898214] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
590 Del Campo JA, Gallego-Durán R, Gallego P, Grande L. Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD). Int J Mol Sci 2018;19:E911. [PMID: 29562725 DOI: 10.3390/ijms19030911] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 16.7] [Reference Citation Analysis]
591 Puchakayala BK, Verma S, Kanwar P, Hart J, Sanivarapu RR, Mohanty SR. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease. World J Hepatol 2015;7:2610-8. [PMID: 26557954 DOI: 10.4254/wjh.v7.i25.2610] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
592 López-velázquez JA, Silva-vidal KV, Ponciano-rodríguez G, Chávez-tapia NC, Arrese M, Uribe M, Méndez-sánchez N. The prevalence of nonalcoholic fatty liver disease in the Americas. Annals of Hepatology 2014;13:166-78. [DOI: 10.1016/s1665-2681(19)30879-8] [Cited by in Crossref: 82] [Article Influence: 11.7] [Reference Citation Analysis]
593 Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab. 2013;27:195-208. [PMID: 23731881 DOI: 10.1016/j.beem.2013.02.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
594 Heidari Z, Gharebaghi A. Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. J Clin Diagn Res 2017;11:OC04-7. [PMID: 28658824 DOI: 10.7860/JCDR/2017/25931.9823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
595 Lai LL, Chan WK, Sthaneshwar P, Nik Mustapha NR, Goh KL, Mahadeva S. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in non-alcoholic fatty liver disease. PLoS One 2017;12:e0174982. [PMID: 28369100 DOI: 10.1371/journal.pone.0174982] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
596 Neagoe CD, Farmazon AS, Amzolini AM, Singer CE, Ianoşi SL, Tutunaru CV, Genunche-Dumitrescu AV, Ianoşi NG, Păun I, Leru PM, Tica OS, Popescu M. The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients. Rom J Morphol Embryol 2020;61:503-11. [PMID: 33544802 DOI: 10.47162/RJME.61.2.20] [Reference Citation Analysis]
597 Musso G, Cassader M, De Michieli F, Paschetta E, Pinach S, Saba F, Bongiovanni D, Framarin L, Berrutti M, Leone N, Corvisieri S, Parente R, Molinaro F, Sircana A, Bo S, Gambino R. MERTK rs4374383 variant predicts incident nonalcoholic fatty liver disease and diabetes: role of mononuclear cell activation and adipokine response to dietary fat. Human Molecular Genetics 2017;26:1747-58. [DOI: 10.1093/hmg/ddw400] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
598 Jaruvongvanich V, Wirunsawanya K, Sanguankeo A, Upala S. Nonalcoholic fatty liver disease is associated with coronary artery calcification: A systematic review and meta-analysis. Dig Liver Dis 2016;48:1410-7. [PMID: 27697419 DOI: 10.1016/j.dld.2016.09.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
599 Mazhar K. The Future of Nonalcoholic Fatty Liver Disease Treatment. Med Clin North Am 2019;103:57-69. [PMID: 30466676 DOI: 10.1016/j.mcna.2018.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
600 Nobili V, Alisi A, Musso G, Scorletti E, Calder PC, Byrne CD. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Crit Rev Clin Lab Sci. 2016;53:106-120. [PMID: 26463349 DOI: 10.3109/10408363.2015.1092106] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
601 Herat L, Rudnicka C, Okada Y, Mochizuki S, Schlaich M, Matthews V. The Metalloproteinase ADAM28 Promotes Metabolic Dysfunction in Mice. Int J Mol Sci 2017;18:E884. [PMID: 28430139 DOI: 10.3390/ijms18040884] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
602 Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res 2013;43:51-64. [PMID: 23332087 DOI: 10.1111/j.1872-034X.2012.01031.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 59] [Article Influence: 14.3] [Reference Citation Analysis]
603 Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology 2015;63:705-12. [DOI: 10.1016/j.jhep.2015.05.006] [Cited by in Crossref: 195] [Cited by in F6Publishing: 160] [Article Influence: 32.5] [Reference Citation Analysis]
604 Zhang P, Feng W, Chu X, Sun X, Zhu D, Bi Y. A newly noninvasive model for prediction of non-alcoholic fatty liver disease: utility of serum prolactin levels. BMC Gastroenterol 2019;19:202. [PMID: 31775658 DOI: 10.1186/s12876-019-1120-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
605 Ortiz-Avila O, Gallegos-Corona MA, Sánchez-Briones LA, Calderón-Cortés E, Montoya-Pérez R, Rodriguez-Orozco AR, Campos-García J, Saavedra-Molina A, Mejía-Zepeda R, Cortés-Rojo C. Protective effects of dietary avocado oil on impaired electron transport chain function and exacerbated oxidative stress in liver mitochondria from diabetic rats. J Bioenerg Biomembr 2015;47:337-53. [PMID: 26060181 DOI: 10.1007/s10863-015-9614-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
606 Masaki S, Hashimoto Y, Kunisho S, Kimoto A, Kitadai Y. Fatty change of the liver microenvironment influences the metastatic potential of colorectal cancer. Int J Exp Pathol 2020;101:162-70. [PMID: 32783302 DOI: 10.1111/iep.12371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
607 Franch-Nadal J, Caballeria L, Mata-Cases M, Mauricio D, Giraldez-García C, Mancera J, Goday A, Mundet-Tudurí X, Regidor E; PREDAPS Study Group. Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study. PLoS One 2018;13:e0198327. [PMID: 29856820 DOI: 10.1371/journal.pone.0198327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
608 Lee SS, Byoun YS, Jeong SH, Woo BH, Jang ES, Kim JW, Kim HY. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. Dig Dis Sci. 2014;59:2967-2974. [PMID: 25069572 DOI: 10.1007/s10620-014-3279-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
609 Alkhouri N, Johnson C, Adams L, Kitajima S, Tsuruno C, Colpitts TL, Hatcho K, Lawitz E, Lopez R, Feldstein AE. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis. PLoS One 2018;13:e0202226. [PMID: 30161179 DOI: 10.1371/journal.pone.0202226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
610 Kao WY, Lin YF, Chang IW, Chen CL, Tang JH, Chang CC, Chang YJ, Wang W. Interleukin-2 receptor alpha as a biomarker for nonalcoholic fatty liver disease diagnosis. J Chin Med Assoc 2021;84:261-6. [PMID: 33306598 DOI: 10.1097/JCMA.0000000000000469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
611 Gao X, Fan JG. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology. J Diabetes. 2013;5:406-415. [PMID: 23560695 DOI: 10.1111/1753-0407.12056] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
612 Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol. 2013;10:645-655. [PMID: 24061205 DOI: 10.1038/nrgastro.2013.182] [Cited by in Crossref: 204] [Cited by in F6Publishing: 171] [Article Influence: 25.5] [Reference Citation Analysis]
613 Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. Journal of Clinical Gastroenterology 2012;46:272-84. [DOI: 10.1097/mcg.0b013e31824587e0] [Cited by in Crossref: 80] [Cited by in F6Publishing: 24] [Article Influence: 8.9] [Reference Citation Analysis]
614 Gabbia D, Dall'Acqua S, Di Gangi IM, Bogialli S, Caputi V, Albertoni L, Marsilio I, Paccagnella N, Carrara M, Giron MC, De Martin S. The Phytocomplex from Fucus vesiculosus and Ascophyllum nodosum Controls Postprandial Plasma Glucose Levels: An In Vitro and In Vivo Study in a Mouse Model of NASH. Mar Drugs 2017;15:E41. [PMID: 28212301 DOI: 10.3390/md15020041] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
615 Fierbinteanu-Braticevici C, Sinescu C, Moldoveanu A, Petrisor A, Diaconu S, Cretoiu D, Braticevici B. Nonalcoholic fatty liver disease: one entity, multiple impacts on liver health. Cell Biol Toxicol 2017;33:5-14. [PMID: 27680752 DOI: 10.1007/s10565-016-9361-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
616 Culafic M, Vezmar Kovacevic S, Dopsaj V, Stulic M, Vlaisavljevic Z, Miljkovic B, Culafic D. A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests. Medicina (Kaunas). 2019;55. [PMID: 31163711 DOI: 10.3390/medicina55060243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
617 Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology 2021. [PMID: 33811367 DOI: 10.1002/hep.31843] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
618 Silva AKS, Peixoto CA. Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation. Cell Mol Life Sci. 2018;75:2951-2961. [PMID: 29789866 DOI: 10.1007/s00018-018-2838-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
619 Harlow KE, Africa JA, Wells A, Belt PH, Behling CA, Jain AK, Molleston JP, Newton KP, Rosenthal P, Vos MB, Xanthakos SA, Lavine JE, Schwimmer JB; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. J Pediatr 2018;198:76-83.e2. [PMID: 29661561 DOI: 10.1016/j.jpeds.2018.02.038] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
620 VanWagner LB, Ning H, Lewis CE, Shay CM, Wilkins J, Carr JJ, Terry JG, Lloyd-Jones DM, Jacobs DR Jr, Carnethon MR. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study. Atherosclerosis. 2014;235:599-605. [PMID: 24956534 DOI: 10.1016/j.atherosclerosis.2014.05.962] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 12.9] [Reference Citation Analysis]
621 Valenti L, Rametta R, Dongiovanni P, Motta BM, Canavesi E, Pelusi S, Pulixi EA, Fracanzani AL, Fargion S. The A736V TMPRSS6 polymorphism influences hepatic iron overload in nonalcoholic fatty liver disease. PLoS One 2012;7:e48804. [PMID: 23144979 DOI: 10.1371/journal.pone.0048804] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
622 Gerage AM, Ritti-dias RM, Balagopal PB, Conceição RDDO, Umpierre D, Santos RD, Cucato GG, Bittencourt MS. Physical activity levels and hepatic steatosis: A longitudinal follow-up study in adults: Physical activity and hepatic steatosis. Journal of Gastroenterology and Hepatology 2018;33:741-6. [DOI: 10.1111/jgh.13965] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
623 Lee CH, Choi SH, Chung GE, Park B, Kwak MS. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver Int 2018;38:2091-100. [PMID: 29660233 DOI: 10.1111/liv.13860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
624 Wang S, Zhang J, Zhu L, Song L, Meng Z, Jia Q, Li X, Liu N, Hu T, Zhou P, Zhang Q, Liu L, Song K, Jia Q. Association between liver function and metabolic syndrome in Chinese men and women. Sci Rep 2017;7:44844. [PMID: 28317840 DOI: 10.1038/srep44844] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
625 Mann JP, Carter P, Armstrong MJ, Abdelaziz HK, Uppal H, Patel B, Chandran S, More R, Newsome PN, Potluri R. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. PLoS One. 2020;15:e0241357. [PMID: 33108366 DOI: 10.1371/journal.pone.0241357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
626 Asrih M, Jornayvaz FR. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? Molecular and Cellular Endocrinology 2015;418:55-65. [DOI: 10.1016/j.mce.2015.02.018] [Cited by in Crossref: 150] [Cited by in F6Publishing: 141] [Article Influence: 25.0] [Reference Citation Analysis]
627 Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H, Hara T, Okajima A, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Kanemasa K, Yasui K, Minami M, Imai S, Itoh Y. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients: ALT in NASH progression. Hepatol Res 2015;45:E53-61. [DOI: 10.1111/hepr.12456] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
628 Chen Y, Xu M, Wang T, Sun J, Sun W, Xu B, Huang X, Xu Y, Lu J, Li X, Wang W, Bi Y, Ning G. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis. 2015;241:145-150. [PMID: 25988358 DOI: 10.1016/j.atherosclerosis.2015.05.002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
629 Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. Journal of Hepatology 2016;65:589-600. [DOI: 10.1016/j.jhep.2016.05.013] [Cited by in Crossref: 515] [Cited by in F6Publishing: 422] [Article Influence: 103.0] [Reference Citation Analysis]
630 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 165] [Article Influence: 17.7] [Reference Citation Analysis]
631 Ozenirler S, Erkan G, Konca Degertekin C, Ercin U, Cengiz M, Bilgihan A, Yilmaz G, Akyol G. The relationship between advanced oxidation protein products (AOPP) and biochemical and histopathological findings in patients with nonalcoholic steatohepatitis: AOPP and nonalcoholic steatohepatitis. Journal of Digestive Diseases 2014;15:131-6. [DOI: 10.1111/1751-2980.12113] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
632 Rowell RJ, Anstee QM. An overview of the genetics, mechanisms and management of NAFLD and ALD. Clin Med (Lond). 2015;15 Suppl 6:s77-s82. [PMID: 26634687 DOI: 10.7861/clinmedicine.15-6-s77] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
633 Peters HPF, Schrauwen P, Verhoef P, Byrne CD, Mela DJ, Pfeiffer AFH, Risérus U, Rosendaal FR, Schrauwen-Hinderling V. Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. J Nutr Sci 2017;6:e15. [PMID: 28630692 DOI: 10.1017/jns.2017.13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
634 Kumar R. Hard clinical outcomes in patients with NAFLD. Hepatol Int 2013;7 Suppl 2:790-9. [PMID: 26202293 DOI: 10.1007/s12072-013-9455-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
635 Muyyarikkandy MS, McLeod M, Maguire M, Mahar R, Kattapuram N, Zhang C, Surugihalli C, Muralidaran V, Vavilikolanu K, Mathews CE, Merritt ME, Sunny NE. Branched chain amino acids and carbohydrate restriction exacerbate ketogenesis and hepatic mitochondrial oxidative dysfunction during NAFLD. FASEB J 2020;34:14832-49. [PMID: 32918763 DOI: 10.1096/fj.202001495R] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
636 Weinstein G, Davis-Plourde K, Himali JJ, Zelber-Sagi S, Beiser AS, Seshadri S. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study. Liver Int 2019;39:1713-21. [PMID: 31155826 DOI: 10.1111/liv.14161] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
637 Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract. 2013;28:40-51. [PMID: 23286927 DOI: 10.1177/0884533612470464] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
638 van den Berg EH, Flores-Guerrero JL, Gruppen EG, de Borst MH, Wolak-Dinsmore J, Connelly MA, Bakker SJL, Dullaart RPF. Non-Alcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: Role of Circulating Branched-Chain Amino Acids. Nutrients 2019;11:E705. [PMID: 30917546 DOI: 10.3390/nu11030705] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
639 Lee HJ, Yeon JE, Ko EJ, Yoon EL, Suh SJ, Kang K, Kim HR, Kang SH, Yoo YJ, Je J, Lee BJ, Kim JH, Seo YS, Yim HJ, Byun KS. Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. World J Gastroenterol 2015;21:12787-99. [PMID: 26668503 DOI: 10.3748/wjg.v21.i45.12787] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
640 Benotti P, Wood GC, Argyropoulos G, Pack A, Keenan BT, Gao X, Gerhard G, Still C. The impact of obstructive sleep apnea on nonalcoholic fatty liver disease in patients with severe obesity. Obesity (Silver Spring). 2016;24:871-877. [PMID: 26880657 DOI: 10.1002/oby.21409] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
641 Sheron N, Moore M, Ansett S, Parsons C, Bateman A. Developing a ‘traffic light’ test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community. Br J Gen Pract. 2012;62:e616-e624. [PMID: 22947582 DOI: 10.3399/bjgp12x654588] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
642 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 732] [Article Influence: 107.6] [Reference Citation Analysis]
643 Lelouvier B, Servant F, Païssé S, Brunet AC, Benyahya S, Serino M, Valle C, Ortiz MR, Puig J, Courtney M, Federici M, Fernández-Real JM, Burcelin R, Amar J. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis. Hepatology 2016;64:2015-27. [PMID: 27639192 DOI: 10.1002/hep.28829] [Cited by in Crossref: 125] [Cited by in F6Publishing: 105] [Article Influence: 31.3] [Reference Citation Analysis]
644 Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014;34:1155-1161. [PMID: 24743428 DOI: 10.1161/atvbaha.114.303034] [Cited by in Crossref: 96] [Cited by in F6Publishing: 50] [Article Influence: 13.7] [Reference Citation Analysis]
645 Chang HT, Pan HJ, Lee CH. Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients. Clin Breast Cancer 2018;18:e677-85. [PMID: 29287963 DOI: 10.1016/j.clbc.2017.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
646 Candia R, Riquelme A, Baudrand R, Carvajal CA, Morales M, Solís N, Pizarro M, Escalona A, Carrasco G, Boza C. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. Liver Int. 2012;32:392-399. [PMID: 22136330 DOI: 10.1111/j.1478-3231.2011.02685.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
647 Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab 2015;19:597-601. [PMID: 26425466 DOI: 10.4103/2230-8210.163172] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
648 Zhang Z, Wang G, Kang K, Wu G, Wang P. Diagnostic accuracy and clinical utility of a new noninvasive index for hepatic steatosis in patients with hepatitis B virus infection. Sci Rep 2016;6:32875. [PMID: 27597515 DOI: 10.1038/srep32875] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
649 Durazzo M, Belci P, Collo A, Grisoglio E, Bo S. Focus on therapeutic strategies of nonalcoholic Fatty liver disease. Int J Hepatol 2012;2012:464706. [PMID: 23209914 DOI: 10.1155/2012/464706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]